Graduate Theses, Dissertations, and Problem Reports
2017

Implications of Primary Cilia and Associated Lysophosphatidic
Acid Signaling in Glioblastoma Biology and Therapy
Yuriy V. Loskutov

Follow this and additional works at: https://researchrepository.wvu.edu/etd

Recommended Citation
Loskutov, Yuriy V., "Implications of Primary Cilia and Associated Lysophosphatidic Acid Signaling in
Glioblastoma Biology and Therapy" (2017). Graduate Theses, Dissertations, and Problem Reports. 6113.
https://researchrepository.wvu.edu/etd/6113

This Dissertation is protected by copyright and/or related rights. It has been brought to you by the The Research
Repository @ WVU with permission from the rights-holder(s). You are free to use this Dissertation in any way that is
permitted by the copyright and related rights legislation that applies to your use. For other uses you must obtain
permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license
in the record and/ or on the work itself. This Dissertation has been accepted for inclusion in WVU Graduate Theses,
Dissertations, and Problem Reports collection by an authorized administrator of The Research Repository @ WVU.
For more information, please contact researchrepository@mail.wvu.edu.

Implications of primary cilia and associated lysophosphatidic acid signaling in
glioblastoma biology and therapy.

Yuriy V. Loskutov

Dissertation Submitted
to the School of Medicine
at West Virginia University

In Partial Fulfillment of the Requirements
for the Degree of

Doctor of Philosophy in
Cancer Cell Biology

Michael Schaller, Ph.D., Chair
Michael Ruppert, Ph.D.
Karen Martin, Ph.D.
Maxim Sokolov, Ph.D.
Peter Stoilov, Ph.D.
Elena Pugacheva, Ph.D., Mentor

Cancer Cell Biology Program
Morgantown, West Virginia
2017
Keywords: LPA, primary cilia, LPAR1, GBM
Copyright 2017 Yuriy Loskutov

Abstract
Implications of primary cilia and associated lysophosphatidic acid signaling in
glioblastoma biology and therapy.
Yuriy Loskutov

The primary cilium is a ubiquitous organelle presented on most human cells. It serves
as a crucial signaling hub for multiple pathways including growth factor and G-protein
coupled receptors. Loss of primary cilia was observed in various cancers, however, the
implications of this event are unclear. Several studies show that loss of cilia promotes cell
proliferation, suggesting that alteration of ciliary-dependent signaling can drive the hyperproliferative phenotype of cancer cells, therefore re-establishing primary cilia or targeting
altered signaling pathways could be a beneficial strategy as an anti-cancer therapy.
Glioblastoma (GBM) is one of the deadliest cancers with a median survival of 14
months. Such rapid progression of the disease is usually due to the very high growth rate
of the tumor and rapid recurrence after surgical resection. Current standard of care for
GBM patients includes aggressive radiation and chemotherapy, thus there is a high
demand for more targeted approaches. Primary cilia formation is drastically decreased in
GBM, however, the role of cilia in glioblastoma proliferation has not been explored. The
overall aim of this work was to elucidate the mechanisms of increases in proliferation
driven by the loss of cilia, and utilize it to target GBM. The cellular origins of GBM are
currently under debate. One of the potential candidates are astrocytes, a highly abundant
type of cell in the brain. Loss of primary cilia in human astrocytes stimulates proliferation
in the presence of serum. Lysophosphatidic acid (LPA) was found to be a serum
component responsible for this phenotype. Lysophosphatidic acid receptor 1 (LPAR1), a
G-protein coupled receptor, was found to be accumulated in primary cilium in both
astrocytes and GBM cells when cilium was present, while previously reported interactors
of LPAR1, Gα12 and Gαq, were excluded from cilium. LPAR1 signaling through Gα12/Gαq
was previously reported to be responsible for cancer cell proliferation. Such
compartmentalization in ciliated cells creates a barrier against unlimited proliferation,
which is one of the hallmarks of cancer.
Inhibition of LPA signaling with the small molecule compound Ki16425 in deciliated,
highly proliferative astrocytes or GBM cells/xenografts drastically suppresses their growth
both in vitro and in vivo. Moreover, Ki16425 brain delivery via PEG-PLGA nanoparticles
inhibited tumor progression in an intracranial glioblastoma patient-derived xenograft
(PDX) model. Overall, in the current studies, a novel mechanism by which primary cilium
restricts proliferation was established. Loss of primary cilia is sufficient to increase
mitogenic signaling, and is important for the maintenance of a highly proliferative cancer
phenotype. Clinical application of LPA inhibitors may prove beneficial to restrict
glioblastoma proliferation and ensure local control of the disease.
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Literature Review
1. Primary cilia: signaling hub/organelle/molecular machine
1.1 Primary cilia structure, maintenance, and function
Primary cilium is a non-motile, microtubule-based organelle. It is formed as a
protrusion of a mature centriole in G1/G0, consists of nine doublets of microtubules known
as an axoneme, and is covered with the plasma membrane (1) (Fig.1). Ciliary
microtubules are built from tubulin α and β dimers with the “+”end located at the tip of the
cilium. The axoneme includes a transition zone linking the cilium to the centriole/basal
body, a doublet zone including both microtubule doublet A (full microtubule) and B (hemitube), and a singlet zone where only A tubes are present (2). The base of the primary
cilium usually emerges from an invagination in the cell plasma membrane known as the
ciliary pocket (3).

Figure 1. Principal components and organization of the primary cilium.
Cilia accumulate multiple receptors and signal transduction components, thus tight
regulation of ciliary trafficking is required. Indeed, an elaborate system of intraflagellar
transport machinery exists, and the core components of this system are intraflagellar
1

transport (IFT) particles (Fig.1). IFT particles consist of motor proteins, IFT-A, IFT-B, and
BBSome complexes (4). Motor proteins include heterodimeric kinesin II complex (KIF3A,
KIF3B and KAP), homodimeric kinesin II complex (KIF17), and IFT dynein complex.
Heterodimeric kinesin II is required for cilium assembly (5) and movement of the IFT
particles along the doublet zone (6). Homodimeric kinesin II seems to be dispensable for
cilium assembly (7) and is required for movement along the singlet zone of the axoneme
(6). IFT-dynein propels the IFT particles from the tip of the cilium back to the cell body
(8).Loss of IFT-dynein results in abnormal, bulging cilia with accumulation of the IFT
particles at the tip (9, 10). IFT-A and IFT-B complexes form the core of IFT particles,
however, the exact function and relation of their components are not clear (11). Several
components, such as IFT88, were reported to be essential for cilium assembly (12). The
BBSome complex derives its name from Bardet-Biedl syndrome, since mutations in its
components cause this disease (13). The BBSome interacts with IFT-A and IFT-B
complexes and is believed to participate in trafficking of the transmembrane proteins
along the cilium (14).
1.2 Mechanisms of assembly/disassembly of primary cilia
Assembly of the primary cilium begins in G1 with a docking of the small cytoplasmic
vesicles to the mother centriole, this is Cep164 and Talpid3-dependent event (15). The
fusion of the small vesicles, which requires EDH1 and EDH3, generates a large ciliary
vesicle encapsulating the growing axoneme (16). After the assembly of the large ciliary
vesicle, Rabin 8 activates Rab8, which promotes cilium elongation (16). Elongation of the
axoneme deforms the ciliary vesicle by creating two membrane surfaces: the sheath
(outer membrane) and the shaft (membrane surrounding axoneme). After the docking of
the mother centriole to the plasma membrane, the ciliary vesicle fuses with it, exposing
the growing cilium to the extracellular environment (17).
Disassembly of the primary cilium is a crucial event for cell cycle progression. As the
cilium is a protrusion of the basal body, it anchors the centriole in the perimembrane area,
thereby preventing it from participation in mitotic spindle formation (18). During the cell
cycle, the cilium is assembled in the G1/G0 phase, fluctuates through S and G2, and gets
disassembled during G2/M transition (19). It is not entirely clear what is the mechanism
2

of cilium disassembly, however, there are several lines of evidence suggesting complex
regulation of this process. Activation of the mitotic kinase Aurora A (AURKA) is a key
player in cilium disassembly, and inhibition or transient depletion of AURKA abolishes
serum-initiated cilia disassembly. The scaffold protein NEDD9, also known as neural
precursor cell expressed developmentally down-regulated protein 9, has been implicated
in the activation of AURKA (20) and is required for cilium disassembly. Histone
deacetylase 6 (HDAC6), an enzyme that deacetylates tubulin (21), is a known
phosphorylation target of AURKA, which increases its deacetylase activity and
destabilizes axonemal microtubules (19). Interestingly, the role of HDAC6 seems to be
dispensable for cilia development, arguing that cilium can be disassembled without
HDAC6 involvement (22). The microtubule-destabilizing kinesins KIF2A and KIF2C are
potential candidates for direct disassembly of axonemal microtubules. Overexpression of
both kinesins triggers cilium disassembly, and KIF2A activity towards cilia is regulated by
polo-like kinase 1 (Plk1) (23). Plk1 is a well-known target of AURKA (24), and moreover,
both KIF2A and KIF2C are known to be regulated by AURKA during mitosis (25, 26),
which puts them in the same AURKA-driven pathway for cilium disassembly. Cell cycle
related kinase (CCRK) and its substrates intestinal cell kinase (ICK) and male germ cellassociated kinase (MAK) were reported to participate in cilium disassembly (27).
Furthermore, CCRK has been implicated in Sonic Hedgehog (Shh) signaling and cilium
length and morphology regulation (28).
1.3 Primary cilia and signal transduction
The complexity and evolutionary stability of the primary cilium suggest that it has some
important functionality. For a long time, primary cilia was known for its role in Hedgehog
signaling, making it indispensable for proper development. In mammalian cells, Shh
receptor patched 1 (Ptch1) localizes to the primary cilium in absence of the ligand, and
excludes the intermediate signaling molecule smoothened (Smo) from it. Protein kinase
A (PKA) promotes proteolytic processing of Gli2/3 into a repressor form, thereby inhibiting
Shh-driven gene expression. In the presence of Shh, Ptch1 translocates to the plasma
membrane, and Smo moves into the cilium. This abrogates PKA activation, promoting
Gli2/3 accumulation in the ciliary tip and activating Gli transcription factor formation (2931).
3

Recently, several of the receptor tyrosine kinases (RTK) were reported to localize to
the primary cilium, and signal in a cilium-dependent manner. Platelet-derived growth
factor receptor (PDGFR) α was found to specifically accumulate in the primary cilium of
fibroblasts, while PDGFRβ was excluded from the cilium. Engineered loss of the cilium
induces rapid degradation of PDGFRα, and loss of its signaling ligand, PDGF-AA, while
preserving signal transduction of PDGF-BB, a PDGFRβ-specific ligand (32). Insulin-like
growth factor 1 receptor (IGF1R) is not exclusive to primary cilium, however, ciliary
localization tends to sensitize it, as activation of the receptor upon stimulation was first
detected in the cilium, and then spread further to the plasma membrane. Similarly to
PDGFRα, loss of cilia drastically decreases ligand-induced activation of IGF1R and
downstream phosphorylation of protein kinase B (AKT) (33). Other RTKs were also
reported to localize to primary cilia, such as epidermal growth factor receptor (EGFR),
which was found in cilia in kidney epithelial cells (34), astrocytes, and neuroblasts (35).
Fibroblast growth factor receptor (FGFR) was reported to localize to motile cilia in the
airways of rhesus monkeys (36), as well as to the basal body of primary cilia in mouse
neural progenitor cells (37). Angiopoietin receptors Tie1/2 localize to primary cilia on the
surface epithelium of the murine ovary, bursa, and extra-ovarian rete ducts (38).
Unfortunately, the significance and role of cilia in these RTK signaling cascades are still
unknown.
Finally, a long list of receptors from the superfamily of G-protein coupled receptors
(GPCR) was found to accumulate in the primary cilium of various cell types (39, 40).
Several cilium-targeting sequences were identified within different types of GPCRs (41,
42). Still, the importance of the cilium for GPCR signaling is very poorly understood. There
is evidence suggesting that the cilium serves as a compartment to scaffold GPCR
signaling components including adenylyl cyclases (AC) 3/5/6 and phosphodiesterase 4C,
thus limiting the spread of downstream signaling (43). In addition to this, it has become
evident that cilia can serve as a platform for GPCR signaling crosstalk through GPCR
hetero-oligomerization (44) and downstream signaling modulation by co-localized
receptors (45). In addition to these, a growing body of evidence indicates that the
downstream effectors of GPCRs, heterotrimeric G-proteins, can also be accumulated or
excluded from primary cilium. For example, Gαs is accumulated in cilia (46), as well as
4

Gαi2 and i3, while Gαi1 is excluded from it (47). Since GPCRs can usually interact with
several types of Gα subunits, such compartmentalization creates a possibility for the
cilium to act as a switch in GPCR signaling.
1.4 Primary cilia loss/dysfunction associated diseases
Mutations in cilium-associated genes can cause a plethora of diseases, collectively
referred to as ciliopathies. Ciliopathies are systemic diseases with a wide variety of
symptoms, usually including the development of abnormalities (polydactyly, situs
inversus), vision loss, cyst formation in multiple organs, obesity, and neurological
disorders (48). A classic example of a ciliopathy is Joubert syndrome (JBTS;
MIM#213300). It is characterized by hypotonia, ataxia, psychomotor delay, an irregular
breathing pattern, and distinctive cerebellar and brain stem malformations. Additional
clinical features include retinal degeneration, cystic kidney disease, ocular colobomas,
occipital encephalocele, hepatic fibrosis, polydactyly, and endocrine abnormalities (49).
Another classic example is Bardet-Biedl syndrome (BBS, MIM#209900), which includes
rod-cone dystrophy, polydactyly, obesity, learning disabilities, hypogonadism, and renal
anomalies. Secondary features include speech delay or disorder, developmental delay,
behavioral abnormalities, brachydactyly/syndactyly, ataxia/poor coordination/imbalance,
mild hypertonia, anosmia, diabetes, fibrocystic liver disease, Hirschsprung’s disease, as
well as dental and cardiovascular anomalies (50). Symptoms and clinical representations
of ciliopathies are largely overlapping, and can be separated by developmental
abnormalities such as polydactyly and situs inversus, which are usually associated with
impaired Shh signaling, or by degenerative processes, such as retinal degeneration, and
different manifestations of dysplasia. The latter is of particular interest, as it occurs
through the whole life of the patient and manifests as cyst formation in the kidney (51)
and liver (52). Interestingly, modeling loss of cilia usually produces a hyperproliferative
phenotype in normal cells (53, 54), thus one may expect to see increased incidence of
cancer in patients with ciliopathies. Unfortunately, no such data is currently available,
however Birt-Hogg-Dubé syndrome, which is associated with an increased incidence of
renal cancer, was recently recognized as a ciliopathy (55).
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2. Primary cilia: potential target for anti-cancer therapy
2.1 Primary cilia and cancer
In multiple cancer types, cilia tend to be lost, however, the role of this event is not
clear. Recent publications suggest that loss of cilia in cancer is a relatively early event in
disease progression. For instance, a drastic decrease in ciliation can be observed in
breast cancer at the stage of non-invasive ductal carcinoma in situ (56). The same
observation holds true in prostate cancer. In preinvasive stage of prostatic intraepithelial
neoplasia, the number of cilia is significantly decreased (57). In a mouse model of
pancreatic cancer, loss of cilia was noted even earlier in pre-cancer lesions. In this model,
pancreatic intraepithelial neoplasia of varying grades can be detected prior to tumor
development, and in these lesions, cilia were already absent (58). On the other hand, a
few reports claim that cilia may be needed for cancer progression in some cases. Since
Shh signaling requires the primary cilium, cancer development in models driven by the
activation of Smo was strongly inhibited by loss of the cilia, but if the driver was the
activated form of Gli, then the cilia loss enhanced tumorigenesis (59, 60). So far, such
observations have only been specific for Shh-driven tumors, which puts them on a list of
peculiar exceptions from the general trend.
So far, cilia loss seems to correlate with tumor progression and also perhaps,
malignant transformation, but is it a driving force for the latter, or is it just a consequence
of transformation? Modeling the loss of cilia in normal cells suggests that it promotes
hyperproliferation in Shh-independent cells. Engineered loss of primary cilia promotes
proliferation in the mouse dermis in vivo (54). In cell culture settings, deciliation of normal
cholangiocytes was sufficient to increase the proliferation rate, and moreover, loss of cilia
promoted attachment-independent growth (53). In the case of Shh-dependent cell
populations such as neural stem cells, ablation of primary cilia seems to inhibit their
proliferation and lead to hypocellularity (61, 62). This observation goes along with tumor
models driven by Smo activation, where cilia are required for tumor initiation (59, 60).
Several approaches have been made to restore primary cilia in cancer cells. In
cholangiacarcinoma cells, depletion or inhibition of the protein HDAC6, which is
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implicated in cilia disassembly (19), was found to robustly restore primary cilia and
suppress proliferation (53). In glioblastoma cells, depletion of CCRK, which is also
implicated in cilium disassembly, was found to significantly inhibit proliferation and restore
ciliation. Interestingly, the number of ciliated cells increased up to 10% in this study, but
depletion of protein KIF3A, which is required for cilia assembly, abrogated all effects of
CCRK depletion on both ciliation and proliferation (27).
Overall, in the majority of cancers, loss of cilia seems to be an early event associated
with an increase in proliferation, and restoration of the cilia, even in small cell populations,
drastically decreases the proliferative capacity of cancer cells.
2.2 Glioblastoma and primary cilia
GBM is one of the most fast progressing cancers, which has a median patient survival
of 13-16 months (63). Currently, treatment options for GBM are very limited, with the
standard of care including aggressive surgical resection, radiation therapy, and
chemotherapy (64). Unfortunately, due to its high invasiveness and fast tumor growth
rate, the majority of GBM patients present signs of recurrent disease within 32-36 weeks
(65). There is therefore a very critical need for the discovery of new targets and the design
of new therapeutic approaches to treat GBM.
Recently, GBM was reported to have a drastically decreased ciliation rate. Only about
10% of GBM cells can assemble cilia. Moreover, electron microscopy analysis of GBM
biopsies showed that the few cilia that they do form possess multiple structural
abnormalities (66-68). Further inhibition of primary cilia assembly in patient-derived GBM
primary cell culture through the introduction of a dominant-negative variant of KIF3A
seems to have a minimal and non-coherent effect on both cell proliferation in vitro and
tumor growth in a mouse intracranial model (69). On the other hand, even minimal
restoration of primary cilia seems to have a tremendous effect on cell proliferation (27).
This clearly suggests that loss of cilia in GBM is a non-random event and may be
associated with the high proliferative capacity of tumor cells. Understanding the
mechanisms of cilia loss in GBM and which pathways lead to increased proliferation upon
loss of the cilia will allow to devise new strategies to battle GBM.
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3. LPA signaling in mammalian cells
3.1 LPA production and function
LPA (lysophosphatidic acid) is a water-soluble lipid metabolite with a wide variety of
cellular functions. LPA promotes proliferation in fibroblasts (70), astrocytes (71), and
multiple other cell types (72-77).In addition to proliferation, LPA promotes cell migration
(76, 77), platelet aggregation (78), smooth muscle contraction (79), and neurite retraction
(80), making it a versatile signal molecule. LPA is present in large amounts in serum (81),
saliva (82), brain (83), and tumor ascites (84).For a long time, the biosynthesis of LPA
was a mystery, but it is now known that there are two main pathways to produce LPA: 1)
autotaxin

(ATX),

a

secreted

lysophospholipase

D

enzyme,

converts

lysophosphatidylcholine (LPC) into LPA (85), and 2) phospholipase A can produce LPA
from phosphatidic acid (86). During development, LPA signaling participates in wound
healing (87), blood and lymphatic vessel formation (88), and brain development (89).
3.2 LPA receptors: expression and function
LPA signals through a family of GPCRs known as lysophosphatidic acid receptors 16 (LPAR1-6) (Fig.2). LPARs have distinctive expression patterns and functions. LPAR1
is expressed in the heart, brain, placenta, skeletal muscle, kidney, pancreas, spleen,
prostate, testis, ovary, small intestine, and colon (90). LPAR1 can interact with the
heterotrimeric G-protein family members Gαi/o, Gα12/13, and Gαq/11 (91), and promote cell
proliferation, migration, survival, and cytoskeleton rearrangements. LPAR1 knockout in
mice can cause a reduction in body weight, minor craniofacial deformities, and increased
neonatal lethality due to decreased suckling behavior (92). LPAR2 is expressed in the
embryonic brain, testis, leukocytes, prostate, spleen, thymus, and pancreas (93).
Predicted interactors of LPAR2 include Gαi/o, Gα12/13, and Gαq/11 G-protein family
members. Surprisingly, LPAR2 knockout in mice did not reveal any gross abnormalities
(94). LPAR3 is broadly expressed, interacts with Gαi/o and Gαq/11 G-protein family
members, and its knockout in mice does not cause any severe gross abnormalities,
however, multiple reproductive defects were observed in LPAR3 -/- females (95). LPAR4
is distinct from LPAR1-3, being structurally close to P2Y purinergic receptors, and
interacts with all four major classes of Gα proteins (91). Knockout of LPAR4 in mice
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produces embryonic lethality caused by impaired vascular development (88). LPAR5 is
also structurally similar to P2Y receptors, and interacts with Gα12/13 and Gαq/11 G-proteins.
LPAR5-knockout mice display decreased nociception and behavioral abnormalities such
as decreased anxiety, motivational changes, and reduced social exploration (96). LPAR6
is the most recently discovered R2Y type of LPA receptor, which interacts with Gα12/13
(97). Knockout of LPAR6 does not seem to cause any alterations in mice behavior or
development, however, it does completely abrogate liver regeneration (98). So far,
nothing is known about the regulation or subcellular localization of LPARs.

Figure 2. Schematic of LPAR signaling.
3.3 LPA/LPAR signaling in cancer
Recently, it became evident that LPA signaling is involved in cancer development and
progression. ATX, the major enzyme involved in LPA production, is highly expressed in
multiple cancer types including neuroblastoma, hepatocellular carcinoma, breast cancer,
renal cancer, and GBM (99). LPA promotes migration in a variety of cancers including
pancreatic (84), prostate (100), breast (101), and GBM (102), as well as promotes
proliferation (75). Mechanistically, LPA can activate multiple pathways inducing
proliferation, potentially in cell type specific manner. In head and neck squamous cell
carcinoma, LPA stimulation causes transactivation of EGFR (74), while in colorectal
9

cancer LPA promotes β-catenin pathway activation (75). In ovarian cancer, LPAR1
requires Gα12 to sustain LPA-driven proliferation (72), and Gαq is required for normal
intestinal epithelium proliferation (103). Depletion of LPAR2 significantly decreases
colitis-associated colon cancer development, while LPA promotes it (104). In addition, the
level of LPA can be used as a prognostic marker in ovarian and gastric cancers (105,
106). Surprisingly, inhibition of LPA signaling is still poorly investigated as a therapeutic
strategy against cancer, however, several works indicate that inhibition of LPAR1 with
Ki16425 is sufficient to abrogate metastasis formation in breast cancer (107, 108) and
inhibition of ATX increases radiosensitivity in GBM (109).
4. Kinesin-13 family motors and their role in cancer
4.1 Kinesin motor superfamily in regulation of microtubule dynamics
The kinesin superfamily is a superfamily of motor proteins capable of moving along
microtubules. Most kinesins target to the growing “+” end of microtubules, but there are
several exceptions. The primary role of kinesins is believed to be the transport of different
cargoes within the cell. The kinesin superfamily includes 16 families of proteins: kinesin1-12 possess a conserved N-terminal motor domain and move towards the “+” end of the
microtubules (110-112), kinesin-13 family members have a motor domain in the middle
and tend to disassemble microtubule lattice (113), and kinesin-14 family members have
a C-terminal motor domain and move toward the “-“ end of microtubules (114). The
kinesin-1, 2, and 3 families are involved in the trafficking of membrane-bound vesicles
and organelles, while the kinesin-4, 5, 6, and 14 families function during mitosis and
participate in spindle microtubule organization and chromosome tethering (115). The
kinesin-8 and 13 families regulate microtubule dynamics by either inhibiting microtubule
elongation or initiating disassembly. Kinesin-8 family members have increased
processivity, promoting accumulation of the motors at the “+” end of long microtubules
(116). At the “+” end, kinesin-8 family members can prevent the addition of new tubulin
dimers to the lattice or can directly remove tubulin from microtubules; however, reports
on the ability of kinesin-8 to directly disassemble microtubules are controversial (117).
Kinesin-13 family members are directly implicated in microtubule disassembly. Their
motor domain localizes in the middle of the protein, and by itself can destabilize
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microtubules (118, 119), but their disassembly rate is significantly enhanced by the
addition of the neck region, which directly precedes the motor domain (120-122).
Mechanistically, kinesin-13 family members disassemble microtubules by bending tubulin
protofilaments at the end of microtubules, locking them in an unstable conformation, and
thus, initiating microtubule catastrophe (123, 124).
4.2 Cellular function of kinesin-13 family members
Kinesin-13 family members include KIF2A, KIF2B, KIF2C and KIF24 proteins (117).
KIF2A is involved in mitosis and is required for bipolar spindle formation (125). It is also
well known to be involved in brain development through suppression of axon branching
and to be required for axon pruning (126, 127). It seems to be involved in the regulation
of cytoskeleton remodeling during cell movement through interaction with Arf GAP using
GTP-binding protein-like, ankyrin repeats and PH Domains1 (AGAP1), but the
implications of this are still vague (128). KIF2B is poorly studied, but it is known to have
a distinct function during mitosis (125). KIF2C is well known for its mitotic functions (125),
and was shown to interact with EB1 and EB3 and target growing microtubules, suggesting
potential participation in rapid tubulin cytoskeleton rearrangements (129). KIF24
participates in the remodeling of centriole microtubules (130) and suppresses cilium
assembly during mitosis (131). KIF2A and KIF2C were recently shown to be able to
induce cilia disassembly (23). Surprisingly, both studies involved KIF24 and KIF2A/C and
did not distinguish between the effects of the kinesin-13 family members on pre-formed
cilia versus de-novo ciliogenesis.
4.3 Kinesin-13 family members in cancer
Recently, the potential involvement of kinesin-13 family members in cancer was
highlighted in multiple publications. For instance, all of the kinesin-13 family members are
associated with progression and poor prognosis of hepatocellular carcinoma (132). High
expression of KIF2A can predict poor prognosis for diffuse large B-cell lymphoma (133)
and gastric cancer (134), and it is associated with high-grade glioma (135). KIF2C was
found to have strong prognostic value in renal clear cell carcinoma (136) and glioma
(137), and was recognized as a potential anti-cancer drug target (138). The reason for
such a strong association with poor prognosis of kinesin-13 family motors, particularly
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KIF2A and KIF2C, is still elusive. However, several lines of evidence indicate that KIF2A
expression is required for maintaining a highly proliferative phenotype and supporting
migration in cancer cells (135, 139). The same observations were made for KIF2C (140,
141). Moreover, depletion of KIF2A or KIF2C is sufficient to induce apoptosis in cancer
cells (142) or to promote senescence (143). Interestingly, both KIF2A and KIF2C induce
primary cilia disassembly (23), and even partial restoration of the primary cilia drastically
inhibits cancer cell proliferation (27, 53). Thus it is tempting to speculate that KIF2A and
KIF2C drive the loss of primary cilia in cancer cells.
5. Aurora kinase A: master regulator of cilium
5.1 AURKA structure and function
AURKA is a mitotic serine/threonine kinase. The Aurora family of proteins consists of
three known members: AURKA, AURKB, and AURKC. The N-terminal domain (1-128aa)
of AURKA targets it to the basal body/centrosomes and allows it to interact with
microtubules during mitosis (144). The N-terminal domain also inhibits the catalytic
activity of AURKA when it is not bound to activating proteins (145) such as NEDD9 and
TPX2. Activation of AURKA results in autophosphorylation of threonine 288 (activational
phosphorylation) (19, 146-148) and serine 51 (protecting from degradation) (149).
Inactivation of AURKA is regulated by protein phosphatase type 2a (PP2a) (150). Active
AURKA is targeted to the centrosome through microtubule binding where it can function
as

a

mitotic

kinase.

During

mitosis,

AURKA

regulates

the

formation

of

Cdk1/CyclinB1complex through phosphorylation and activation of cdc25b phosphatase,
which removes inhibitory phosphorylation from Cdk1 (151).Accumulation of AURKA is
required for centrosome maturation and segregation (152). After nuclear envelope
breakdown, AURKA is targeted to the mitotic spindle in complex with the microtubulebinding protein TPX2 (146). Depletion of AURKA in normal cells results in G2/M arrest or
the formation of a monopolar spindle, causing an inability to separate DNA and
subsequent cell death (153).
5.2 Role of AURKA in regulation of the ciliary dynamics
Most AURKA studies focus on its role in mitosis and G2/M AURKA activation.
Recently, a non-mitotic role of AURKA as a master-regulator of cilia disassembly became
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evident. Serum stimulation of G1/G0-synchronized cells yielded activation of AURKA that
was spatially restricted to the centrioles, and also cilia disassembly. In these settings,
disassembly of the cilia occurs in two waves: first, within 1-2 hours after serum stimulation,
and second, after 18-24 hours. The latter represents G2/M transition, but the first wave
occurs during G1. Inhibition or depletion of AURKA completely abrogates the disassembly
of cilia, while injection of the cells with pre-activated AURKA induces rapid deciliation (19).
The exact mechanism of AURKA activation during the initiation of cilium disassembly has
yet to be elucidated. However, several proteins participating in this event have already
been established. Loss of NEDD9, a phosphorylation-independent AURKA activator,
severely blunted cilia disassembly in response to serum (19). Calmodulin was shown to
directly activate AURKA in a Ca2+-dependent manner, and binding to calmodulin is a
prerequisite for serum treatment-induced cilia disassembly (154). Pitchfork (Pifo) also
interacts directly with AURKA and promotes AURKA activation during cilia disassembly
(155).

Figure 3. Schematic of regulation of human KIF2C through phosphorylation.
5.3 AURKA and KIF2C interface in mitosis and cilia
KIF2A and KIF2C, microtubule-destabilizing kinesins, are potential candidates for
direct disassembly of the cilia (23). During mitosis, AURKA regulates spindle targeting of
both KIF2A and KIF2C, and interestingly, AURKA phosphorylation of KIF2A suppresses
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its microtubule depolymerizing activity and suppresses spindle microtubules binding (25).
KIF2C phosphorylation of serine 192 by AURKA can also suppress its depolymerization
activity, however, the main effect of AURKA seems to be due to the phosphorylation of
serine 719 (xenopus)/ 715 (human), leading to the redistribution of KIF2C to bipolar
spindle microtubules (26). Plk1, a direct target of AURKA, can also phosphorylate serine
715 and enhance depolymerization activity of KIF2C (156). In non-mitotic ciliated cells,
overexpression of KIF2A or KIF2C initiates disassembly of cilia, but KIF2A was more
potent (23). The observations were made in a serum-free media synchronized cell
population, where AURKA is mostly inactive. Taking previously discussed data into
account, activation of AURKA may drastically change the picture, since it will tend to
inhibit KIF2A and activate KIF2C (Fig.3).
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Abstract
The primary cilium is a ubiquitous organelle presented on most human cells. It is a
crucial signaling hub for multiple pathways including growth factor and G-protein coupled
receptors. Loss of primary cilia, observed in various cancers, has been shown to affect
cell proliferation. Primary cilia formation is drastically decreased in glioblastoma (GBM),
however, the role of cilia in normal astrocyte or glioblastoma proliferation has not been
explored. Here we report that loss of primary cilia in human astrocytes stimulates growth
rate in a lysophosphatidic acid (LPA)-dependent manner. We show that lysophosphatidic
acid receptor 1 (LPAR1) is accumulated in primary cilia. LPAR1 signaling through
Gα12/Gαq was previously reported to be responsible for cancer cell proliferation. We found
that in ciliated cells, Gα12 and Gαq are excluded from the cilium, creating a barrier against
unlimited proliferation, one of the hallmarks of cancer. Upon loss of primary cilia, LPAR1
redistributes to the plasma membrane with a concomitant increase in LPAR1 association
with Gα12 and Gαq. Inhibition of LPA signaling with the small molecule compound Ki16425
in

deciliated

highly

proliferative

astrocytes

or

glioblastoma

patient-derived

cells/xenografts drastically suppresses their growth both in vitro and in vivo. Moreover,
Ki16425 brain delivery via PEG-PLGA nanoparticles inhibited tumor progression in an
intracranial glioblastoma PDX model. Overall, our findings establish a novel mechanism
by which primary cilium restricts proliferation and indicate that loss of primary cilia is
sufficient to increase mitogenic signaling, and is important for the maintenance of a highly
proliferative phenotype. Clinical application of LPA inhibitors may prove beneficial to
restrict glioblastoma growth and ensure local control of disease.
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Introduction
The primary cilium is a ubiquitous, microtubule-based organelle which is built on top
of a membrane-anchored basal body. Primary cilium is an important negative regulator
of proliferation and a key sensory organelle. It serves as a hub for multiple signaling
cascades including receptor tyrosine kinase (1), Sonic hedgehog (Shh) (2), and G-protein
coupled receptors (GPCRs) (3). Disassembly of primary cilium leads to release of the
basal body, also called the mother centriole, which is required for mitotic spindle formation
and mitosis. Multiple mitotic kinases initiate cilium disassembly including AURKA, Plk1,
and Nek2 (4-6). Centrosome sequestration is considered one of the primary mechanisms
of negative regulation of proliferation by primary cilium. Nevertheless, cilium shortening
and disassembly is often observed immediately after growth factor stimulation in
interphase (4). The role of this short-term disassembly in cell proliferation is currently
unknown. Recent publications suggest that in different types of cancer including breast,
prostate, renal, and glioblastoma (GBM), cilia tend to be lost (7-10). However, the
importance of this event on tumor maintenance and progression or treatment is not well
understood.
Several studies report that loss of primary cilia in normal cells increases proliferation
and supports attachment-independent growth (11, 12), which are common hallmarks of
cancer. Attempts to restore primary cilia in cancer cells yield a significant inhibition on
proliferation (12, 13). These observations suggest that cilia loss can promote/sustain a
highly proliferative phenotype. However, in a subset of Sonic hedgehog (Shh)-dependent
medulloblastomas, presence of cilium is mandatory (14) for cancer maintenance,
therefore studies on specific cancer subtypes are warranted to establish cilia’s role in
tumor biology and potential therapeutic applications.
Astrocytoma is the most commonly diagnosed adult brain cancer (15), which often
progresses to GBM. The majority of GBM patients succumb to the disease within 13-16
months (15). GBM is a highly proliferative disease with limited treatment options (16).
Lysophosphatidic acid (LPA) is an abundant mitogen in brain tissue (17). LPA acts
through binding of heterotrimeric G-protein coupled receptors (LPAR1-6). It was
previously reported that LPAR1 can signal through Gαi, Gα12, and Gαq family members
(18, 19). LPA stimulates cell proliferation in astrocytes (20) and cancer cells (21).
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Astrocytes are abundant glial cells and well known for their ability to proliferate, especially
in the activated state (22), and were previously reported as the potential cells of origin for
GBM (23).
In our current work, we establish that loss of primary cilia promotes proliferation of
primary non-transformed human astrocytes, providing permissive conditions for
transformation in an LPA-dependent manner. GBM primary cells, with a decreased
occurrence of primary cilia, were also sensitive to LPA and LPAR1/3 inhibition.
Mechanistically, we found that LPA-LPAR1-driven mitogenic signaling was restricted in
cells with primary cilium due to compartmentalization of LPAR1 and its downstream
effectors, Gα12 and Gαq, in cilia and in cytoplasm, respectively. LPAR1 was redistributed
to the plasma membrane upon loss of primary cilium, thus enabling its binding to Gα12
and Gαq, and therefore suggesting that redistribution of LPAR1 is a key mechanism
driving proliferation in a cilia-dependent manner.
Inhibition of LPAR1/3 with the small molecule inhibitor Ki16425 significantly reduces
cell growth rate only in deciliated astrocytes. Likewise, patient-derived GBM proliferation
was stimulated by LPA and abrogated by Ki16425 in a dose-dependent manner.
Importantly, the growth of GBM patient-derived xenografts in vivo was drastically
decreased upon Ki16425 administration as a monotherapy without significant side effects.
Taken together, our findings indicate that loss of primary cilia eliminates spatial
barriers curbing proliferation, thus unlocking the potential for unlimited proliferation. LPA
is one of the key mitogenic factors driving highly proliferative GBM with no or very low
basal ciliation, therefore clinical interventions based on inhibiting LPA signaling may
significantly improve GBM patient survival and local disease control.
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Results
Loss of primary cilium promotes proliferation of astrocytes.
Human astrocytes (HA) can form primary cilia. Incubation in serum-free media (SFM)
promotes ciliation resulting in nearly 80% of cells having cilia (Fig.1A-B). This ciliation rate
is similar to that observed in vivo (24). To allow for long term experiments, the primary
human astrocytes (HA) were immortalized using SV40 large T antigen (HA-LTA) (25).
Immortalization by LTA did not affect ciliation, which was similar to the parental astrocytes
(Fig.S1A). To test how loss of primary cilia affects proliferation of primary (HA) or
immortalized (HA-LTA) astrocytes, we utilized shRNA-driven knockdown of IFT88 or
KIF3B, which are well characterized components of cilium assembly machinery (26, 27).
Two shRNAs were used to target IFT88 or KIF3B resulting in up to a 90% knockdown
(Fig1.C). Depletion of either IFT88 or KIF3B was sufficient to decrease ciliation to 5-15%
(Fig.1D-E). These ciliation rates are similar to tissue biopsies from GBM patients (28).
The loss of primary cilia resulted in a significant increase in growth rate of both
immortalized and primary astrocytes (Fig1.F-G). Interestingly, this difference in growth
rate was observed between ciliated (shCon) and deciliated (shKIF3B or shIFT88) cells
only upon addition of serum-supplemented media (SSM), but not in SFM. Addition of SSM
caused resorption of primary cilia in control cells in a biphasic wave pattern (Fig.S1B),
which has been described previously for other cell types (4). These findings indicate that
loss of primary cilia by itself does not promote proliferation, but rather increases the
response to some mitogenic stimuli present in serum.
Loss of primary cilia changes spatio-temporal response to mitogen stimulation.
To elucidate the potential mechanism underlying cilia-dependent changes in cell
growth rate, a time course analysis of synchronized (SFM starved) astrocytes was
performed. Phosphorylation of ERK1/2 (Thr202/Tyr204) and AKT (Ser473), common
readouts for a variety of mitogen and pro-survival stimuli, was used to follow the seruminduced response. In agreement with previous reports, addition of 10% serum triggers a
rapid (5-60min) increase in ERK1/2 and AKT phosphorylation followed by a gradual
decrease (60-240min) in phosphorylation in all cell lines independent of ciliation status
(Fig.2, Fig.3). Interestingly, the amount of phosphorylated ERK1/2 was twofold higher in
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deciliated

cells

(shKIF3B

or

shIFT88)

than

in

control

(shCon)

based

on

immunofluorescent and western blot assays (Fig.2A-F). Contrary to ERK1/2,
phosphorylation of AKT was twofold lower in deciliated cells than in control (Fig.3A-F),
indicating that changes in the pattern and intensity of the signal initiation/propagation act
in a cilia-dependent manner.
Lysophosphatidic acid signaling is critical for increased proliferation in
deciliated astrocytes.
To define the mitogene/s potentially responsible for the hyperproliferative phenotype
of deciliated astrocytes, charcoal-stripped serum was used. Charcoal stripping is an
efficient way to deplete bioactive lipids, as well as hormones and some vitamins (29), but
preserve protein-based growth factors. Surprisingly, charcoal-treatment of serum (cSSM)
was sufficient to completely abrogate the increase in growth rate observed in deciliated
astrocytes (Fig.4A). One of the most abundant lipid-based mitogens found in serum is
lysophosphatidic acid (LPA), which binds to LPA receptors (LPARs) to elicit a response.
To test if LPA is involved in deciliation-dependent stimulation of proliferation, a small
molecule inhibitor of LPAR1-3, Ki16425 (30), was used. Similar to cSSM, addition of
Ki16425 to SSM was sufficient to abrogate the deciliation-dependent increase in growth
rates, without any effect on growth of ciliated astrocytes (SSM vs. SSM+Ki16425)
(Fig.4B). Moreover, addition of LPA alone to the serum-free medium (SFM) was sufficient
to stimulate proliferation of astrocytes, and partially recapitulate the difference observed
between ciliated and deciliated cells in the presence of serum (Fig.4B). As expected, LPA
addition resulted in a pattern of ERK1/2 and AKT phosphorylation similar to the one
observed during serum stimulation (Fig.4C-E). Surprisingly, treatment with EGF, bFGF,
PDGF-A/B, or HGF as single agents was neither sufficient to induce proliferation
(Fig.S2A) nor able to recapitulate the difference in phosphorylation of both ERK1/2 and
AKT (Fig.S2B-C, Fig.S3A-B) previously observed between ciliated and deciliated cells
(Fig.2E, Fig.3E). Interestingly, addition of a cocktail of protein growth factors (GFs)
including EGF, bFGF, and B27 supplement along with LPA was sufficient to fully
recapitulate the phenotype observed with addition of serum (Fig.4F). These findings
indicate that LPA signaling is responsible for the highly proliferative phenotype observed
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in astrocytes with disrupted ciliogenesis, but it requires additional growth factors to amplify
its effect.
LPAR1 localizes to primary cilia.
To understand the mechanisms underlying cilia-dependent action of LPA, the
subcellular localization of LPARs and Gα subunits participating in downstream signal
transduction pathways was analyzed. A panel of LPARs fused with 3xFLAG-tag was
exogenously expressed in astrocytes followed by immunofluorescent analysis using antiFLAG antibodies. LPAR1 and LPAR3, but not LPAR6, were consistently localized in
primary cilium (Fig.5A, S4A-B). Interestingly, in deciliated cells, both LPAR1 and LPAR3
were targeted to the plasma membrane (Fig.S5A-B). To exclude the possibility of
overexpression-driven cilium targeting of LPAR1, we validated several anti-LPAR1
antibodies for immunofluorescent staining, using CRISPR-Cas9 driven LPAR1 depleted
astrocytes as a control (Fig.S6). Utilizing validated antibodies we were able to confirm
that endogenous LPAR1 localizes to primary cilium when it is present (Fig.S7).
Analysis of the cellular localization of multiple Gα subunits shows that only Gαs
consistently targeted to primary cilia, similar to previous reports (31). However, whether
other Gα subunits enter primary cilia is currently unknown. We found that Gαi1, Gαq, and
Gα12 did not display ciliary localization, but rather diffuse cytoplasmic and plasma
membrane staining (Fig.5C). Such a pattern of compartmentalization suggests that
LPARs may engage in interactions with different Gα subunits depending upon presence
or absence of primary cilia.
LPAR1 directly binds to Gα12 and Gαq subunits in deciliated cells.
To test this hypothesis, immunoprecipitation analysis was performed in shCon,
shIFT88, and shKIF3B astrocytes transiently overexpressing 3xFLAG-LPAR1. Based on
sequence similarity, LPAR1 is predicted to interact with Gαi, Gαq, and Gα12 (19). No
interaction was detected between LPAR1 and Gαs. The robust co-immunoprecipitation of
Gα12 and Gαq with LPAR1 was noted, being 2-3 times higher in deciliated astrocytes
(Fig.5D). Previously, LPAR1 was reported to promote cancer cell proliferation specifically
through Gα12 (18). Gαq was also reported to transmit pro-proliferative signals in cancer
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(32). We concluded that LPAR1 is sequestered in primary cilia, which prevents its
interaction with cytoplasmic Gα12 and Gαq, restricting its proliferative signaling. Loss of
cilia promotes LPAR1 interaction with Gα12 and Gαq, thus promoting the proliferative
response to LPA (Fig.5D).
LPA signaling drives GBM proliferation both in vitro and in vivo.
To evaluate our findings in disease-relevant settings, previously characterized GBM
patient-derived cells and xenografts (33, 34) of two molecular subtypes (classical-GBM6
and mesenchymal-GBM12) were used. In agreement with previous reports (28), only 510% of GBM cells in vivo (GBM xenografts in mice, Fig.S8A-B) or in vitro (primary cells
short term cultures, Fig.S8C-D) possess primary cilia. LPAR1 staining in GBM6 and 12
cells shows similar pattern to primary astrocytes (Fig.S8E). LPA was previously
implicated in GBM progression and invasiveness (35), hence its effects on GBM cell
proliferation was evaluated. Upon addition of LPA in serum-free GF-supplemented media,
a significant increase of primary GBM cell growth rate in vitro was observed (Fig.S8F),
while addition of the LPA inhibitor, Ki16425, to SSM decreases GBM cell growth rate in a
dose-dependent manner (Fig.S8G).
Similar to in vitro studies, daily intraperitoneal administration of 30mg/kg Ki16425 as
a monotherapy over 4-5 weeks significantly decreased the growth of subcutaneously
transplanted GBM xenografts in immunodeficient mice (Fig 6A-E). In agreement with in
vitro PDX cell line proliferation data (Fig.S8G), the number of mitotic figures in Ki16425treated tumors (Fig 6D, E) was twofold lower. Overall, these findings indicate that LPA is
an important mitogen in GBM and inhibition of LPA signaling is a viable option to improve
anti-GBM therapy.
PEG-PLGA Ki16425 loaded nanoparticles slow down GBM growth in brain.
To assess the feasibility of targeting GBM with Ki16425 in patients, its effect on GBM
growth was evaluated in an intracranial mouse model. Preliminary studies indicated that
the regimen used for the subcutaneous GBM PDX experiment was not efficient in the
intracranial model (Fig.S9A-B), suggesting that Ki16425 is not capable of crossing the
blood brain barrier. To overcome this issue, we used a PEG-PLGA nanoparticle-based
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delivery system (36) to allow for robust Ki16425 brain entry. Fluorescently labeled
nanoparticles rapidly entered the brain upon IP injection and were gradually
excreted/degraded over the next 12h period (Fig.S9C-D).To account for this decay, the
regimen was modified to 30mg/kg Ki16425 loaded into nanoparticles and delivered every
12h. Mice were intracranially injected with 5x105 GBM12 cells and tumor growth was
monitored weekly via MRI. Upon tumors reaching 5mm3, mice were randomly assigned
to Ki16425 or a vehicle loaded nanoparticles control group. Over 2 weeks of treatment,
the Ki16425 nanoparticle-treated group showed a twofold decrease in tumor progression,
compared to control (Fig.7A-B). In agreement with our previous experiments, the number
of mitotic cells was decreased twofold (Fig.7C-D). These findings show that Ki16425 with
a proper delivery method can significantly suppress GBM progression, and potentially, in
combination with the current standard of care, improve local disease control and GBM
patient survival.
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Discussion
Primary cilium is well known for its role in multiple signaling cascades (1, 2, 11).
Primary cilia length and the number of cells with cilium is significantly reduced or lost in
multiple cancer types including GBM (7-10). Moreover, several studies have noted an
increase in cell proliferation upon loss of primary cilia (11, 12). The proposed mechanism
of cilia-driven proliferation control involves the sequestration of basal body (mother
centriole) and the inability to form the mitotic spindle (37). Previously, it was shown that
primary cilium disassembly is biphasic: a first wave of fast, transient disassembly within
1-2h after exposure to mitogenic stimuli (4), followed by a second wave of disassembly
at 18-24h, which coincides with mitotic entry. The role of the first wave of cilium
disassembly in mitogenic signaling is currently unknown, as is the mechanism/s
underlying the increase in proliferation upon loss of primary cilia.
Several pro-proliferative signaling cascades are reported to require primary cilium for
proper signal transduction. For instance, PDGF-AA signaling through PDGFRαα is lost in
deciliated fibroblasts, therefore stimulation with PDGF-AA does not cause ERK1/2 or AKT
activation (38); however, the overall proliferation effect of cilia loss was not evaluated in
this work. SHH signaling is well-studied in conjunction with primary cilium. Loss of cilia
ablates SHH signaling and Shh-driven proliferation (39), and correspondingly, Shh-driven
cancers have a tendency to maintain high ciliation rates (14, 40). On the other hand,
ciliary localization of IGF1R (41) and Notch (11) signaling is needed for differentiation and
restriction of cell proliferation. Importantly, cilium can selectively sequester signaling
components like GPR88 (42) and LPAR1/3 (Fig.5, S4) from their interaction with ciliaexcluded co-factors, thus conferring selectivity on signal propagation/amplification
through the lateral segregation of receptors. This strongly argues that the effect of primary
cilia on proliferation is context-dependent, with pro-proliferative effects during
development through Shh signaling and anti-proliferative effects in more differentiated
cells.
In GBM, the complete inhibition of ciliogenesis seems to have minimal and noncoherent effects on overall proliferation and tumor progression (43). Nevertheless,
ciliation compared to normal brain cells is drastically decreased (9), supporting an antimitogenic function of primary cilium in GBM. Our current findings suggest that the
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engineered loss of primary cilia in normal human astrocytes phenotypically closely mimics
transient cilium disassembly (Fig.S1B), and also resembles cilia loss in GBM cells
(Fig.S8B, D). The increase in growth rate observed in deciliated cells (Fig.1F, G) suggests
that transient cilia disassembly may be a key event augmenting mitogenic signaling.
Mechanistically, we found that loss of primary cilia in human non-transformed astrocytes
results in the amplification of ERK1/2 phosphorylation and promotes proliferation in an
LPA-dependent manner (Fig.2, Fig.4). Interestingly, phosphorylation of AKT in response
to LPA or serum stimulation was decreased in deciliated astrocytes (Fig.3). This can be
attributed to inactivation of PDGFRαα (38) and IGF1R (41) driven signaling, and adds to
the understanding of increased stress sensitivity in deciliated astrocytes (44). These
findings support the idea that loss of primary cilia changes the pattern of the cellular
response to mitogen stimulation, resulting in higher, more sustainable ERK1/2 activation
thus explaining the increase in proliferation, but revealing the potential vulnerability of
deciliated cells to stress via a decrease in pro-survival signaling (pAKT). Since GBMs
usually have high pAKT levels (45) and we did not observe the transformation of deciliated
astrocytes, we conclude that additional hit/s such as those well-known for GBM including
RTK amplification/PTEN inactivation/PI3K activation, are required for overcoming the
decrease in AKT activation.
Previously, LPA was implicated in the regulation of cell migration and proliferation (21,
35), however, the role of primary cilia in these signaling pathways was not explored. The
LPA receptors (LPAR1/3) are specifically localized to primary cilium, but the LPAR
downstream effectors, Gα12 and Gαq, are excluded from it (Fig.5, S4). Both Gα12 and Gαq
activation is known to be implicated in cancer cell proliferation and cancer progression
(46, 47). For Gα12, activation through LPAR1 specifically was reported in ovarian cancer
cells (18). Our findings support the notion that in the absence of primary cilia, LPAR1
localizes to the plasma membrane and interacts with Gα12 and Gαq (Fig.5D, S5, S7).
However, further research is required to pinpoint the intracellular compartment for Gα12
and Gαq and endogenous LPAR1 interaction. Hence, loss of primary cilia could be
responsible for increased proliferation in a subset of cancers, and thus cilia restoration or
the manipulation of cilia-dependent signaling such as LPA could be used to develop new
therapeutic approaches to fight cancer.
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GBM cells seem to be highly dependent on LPA as a mitogen, since inhibition of LPA
signaling with Ki16425 abrogates their growth in vitro, and in both subcutaneous and
intracranial GBM models (Fig.S8, Fig.6, Fig.7). Interestingly, the magnitude of the
Ki16425 effect was the same between two in vivo models (Fig.6, Fig.7), suggesting that
LPA signaling is equally engaged in both of them. LPA is known to be highly abundant in
brain (3.7-35 pmol/mg) and serum concentration of LPA was reported to be close to this
range (4-15.5 µM) (17). In addition, GBMs were reported to increase LPA production by
secreting autotaxin (48). However, further studies are required for comprising the LPA
levels in GBM PDXs grown in subcutaneous versus brain settings.
GBM6 and GBM12 used in the current study are of classical and mesenchymal
molecular subtypes respectively, and are highly aggressive in mouse models (33, 34).
Both of these subtypes are associated with rapid disease progression and poor
prognosis. Our in vivo experiments clearly show that targeting LPA signaling yields a
twofold reduction of tumor growth, specifically through a decrease in the proliferation rate
of tumor cells (Fig.6, Fig.7). Moreover, utilizing a PEG-PLGA nanoparticles delivery
system confirmed the effectiveness of targeting LPA signaling in intracranial settings. The
median survival of GBM patients with the current standard of care including aggressive
surgery, radiation, and chemotherapy (49) is about 12 months (15), with the majority of
patients experiencing recurrence within 32-36 weeks (16). Targeting LPA signaling can
prove to be highly beneficial in addition to standard care, since LPA is implicated in
proliferation and migration/invasion (21, 35). Further studies are required, but based on
our findings, we expect a substantial increase in recurrence-free survival upon inhibition
of LPA signaling.
Overall, our data supports the role of LPA signaling in cancer cell proliferation, and for
the first time, highlights primary cilia as a switch for the interpretation of LPA as a mitogen.
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Materials and Methods
Cell lines and reagents
Human astrocytes isolated from human cortex (1800) were obtained from ScienCell
Research Labs and maintained in DMEM/F12, supplemented with 10% heat-inactivated
FBS, Antibiotic-Antimycotic (ThermoFisher) and 10 μg/ml of gentamycin (MP
Biomedicals). Cells were propagated and cryopreserved at passage 2, for all studies cells
were not passaged more than 10 times or 8 weeks, no authentication or mycoplasma
testing were performed. For immortalization, primary astrocytes at passage 5 or 6 were
cultured until 50–75% confluency and transfected with SV40 large T-antigen construct
(25), followed by selection with 500μg/ml G418 (Sigma) until resistant colonies were
formed. GBM6 and 12 PDXs (33) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic,
Rochester, MN) through a shared MTA agreement, no authentication or mycoplasma
testing were performed. PDXs were maintained and used for intracranial injections or
primary cell culture isolation as previously described (34). A list of antibodies and their
used applications is outlined in Table S1. shRNA constructs were obtained from
Dharmacon and are outlined in Table S2. All primers were purchased from IDT
Technologies or Invitrogen, the sequences of which are reported in Table S3. The
following reagents were used: Lysophosphatidic acid (LPA, Cayman Chemical), EGF and
PDGF-AB (Sigma), HGF (R&D Technologies), bFGF (Peprotech), B27 supplement
(ThermoFisher), Ki16425 (ApexBio). For lysophosphatidic acid stimulation experiments,
bovine serum albumin (BSA; BP1600, Fisher Scientific) was used as a carrier and was
added to all cells to a final concentration of 0.1%.
Western blotting
Western blotting was performed using standard procedures (50). Primary antibodies
used are outlined in Table S1. Secondary anti-mouse and anti-rabbit HRP-conjugated
antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed by
chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were
quantified using the digital electrophoresis documentation and image analysis software
GeneTools (Syngene Corp.), with signal intensity normalized to either α-tubulin or
GAPDH.
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Immunofluorescent cell analysis
Cells were processed as previously described (4). Primary antibodies used are
outlined in Table S1. Secondary antibodies included AlexaFluor 488, 555, and 647
(ThermoFisher). Images were captured using a standard setting by an LSM510 confocal
microscope (Zeiss) (50). All images represent whole-cell 3D reconstructed projections
with 0.4μm steps. All quantifications were done using ImageJ (NIH).
Cell growth/proliferation analysis
Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH).
Cells were plated at 1x104 cells per well and grown in the specified conditions for five
days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per
well were analyzed with at least three replicates per independent experiment; each graph
represents at least three independent experiments.
Fluorescent immunohistochemistry (F-IHC)
Deparaffinization and rehydration of 4-5µm thin sections was performed as following:
1) three times for 3 min in xylene, 2) three times for 2 min in 100% ethanol, 3) 2 min in
95% ethanol, 4) 2 min in 80% ethanol, 5) 2 min in 70% ethanol, and 6) 5 min in 1XTBS.
Antigen retrieval was done using 98°C citrate buffer, pH 6.0 for 20 minutes. Sections were
blocked for 60 min with 5% BSA, 1XTBS solution and stained with the indicated primary
antibodies. Secondary antibodies included AlexaFluor-488, 555, and 647 (ThermoFisher)
and sections were mounted with ProLong Gold DAPI-containing media (ThermoFisher).
Images were captured using LSM510 confocal microscope as previously described (50)
(Zeiss). All images represent whole-cell 3D reconstructed projections with 0.4µm steps.
All quantifications were done using ImageJ (NIH).
LPAR cloning
For robust expression and detection of LPARs, pcDNA3.1 vector was modified as
previously described (51). Briefly, the insert containing the cleavable ER-targeting
sequence followed by a 3xFLAG-tag and multiple cloning site (Table S3) was synthesized
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through String™ service (ThermoFisher) and cloned into pcDNA3.1 between HindIII and
SalI restriction sites. LPAR1, 3, 6 cDNA was amplified from a Human Mammary Epithelial
Cells (HMECs) cDNA library kindly provided by Dr. Alexey Ivanov (West Virginia
University, Morgantown, WV); primers are shown in Table S3. The generated inserts were
cloned into pcDNA3.1 ER-3xFLAG between BamHI and XhoI restriction sites. All
constructs were validated by sequencing.
Immunoprecipitation
For LPAR1 immunoprecipitation, 3xFLAG-LPAR1 was transiently overexpressed in
cells pre-incubated for 24h in serum-free media. Cells were lysed as previously described
(52). 3xFLAG-LPAR1 was precipitated with anti-FLAG M2 affinity gel (Sigma) and used
for subsequent Western blot analysis.
Animal experiments
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) immunodeficient male mice (The Jackson
Laboratory) were housed in the West Virginia University Animal Facility under pathogenfree conditions with an approved Institutional Animal Care and Use Committee protocol.
For subcutaneous injections, 100µl of GBM6 or GBM12 tumor mash mixed 1:1 with
Matrigel (Corning) was injected into the mice flanks. For intracranial injections, transient
primary cell cultures were established as previously described (34), and 5x105 cells in 5µl
of Ca/Mg-free Dulbecco modified Phosphate Buffer Saline (DPBS) were administrated
into the mouse cortex via stereotactic device-guided injection (34). Subcutaneous tumor
growth was assessed weekly via caliper measurements; treatment was initiated upon
tumor volume reaching 100mm3. Intracranial tumor volume was assessed weekly via
contrast enhanced MRI (53) or twice a week via bioluminescence imaging (54); treatment
was initiated upon tumor volume exceeding 5mm3. Animals were randomly assigned to
the treatment group by simple randomization, investigator was single blinded during
group allocation. Mice bearing subcutaneous tumors were intraperitoneally injected with
30mg/kg Ki16425 in 95% corn oil/5% DMSO or vehicle alone daily. For the intracranial
model, mice were administered 30mg/kg Ki16425 loaded into PEG-PLGA nano-particles
in PBS or given nano-particles alone twice daily. All animals were euthanized upon
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reaching a moribund condition, according to the WVU IACUC Tumor Development and
Tumor Scoring in Rodents policy.
Contrast enhanced Magnetic Resonance Imaging (MRI)
To visualize the intracranial tumors, mice were intraperitoneally injected with
gadolinium-DTPA (contrast reagent, BioPAL) to a final concentration of 2mmol/kg (55),
and imaged with a compact MRI system (ICON, Bruker). Images were taken with T1
weighted RARE sequence (echo time: 26.23ms; repetition time 1984.158ms; averages:
8; rare factor: 6). Overall time of scan was 25min and final resolution was 0.125mm for
all axes. Stack images were reconstructed and analyzed using ImageJ (NIH).
Animal bioluminescence imaging
Mice were imaged twice a week for quantitative evaluation of tumor growth as
previously described (56). Images were obtained using the IVIS Lumina-II Imaging
System and Living Image-4.0 software (PerkinElmer).
PEG-PLGA nano-particles
Nano-particles were prepared as previously described (36). Briefly, PEG-PLGA and
Ki16425 were dissolved in acetone and added dropwise into water. The nano-particles
were stirred for 2 h at 40°C before being collected by centrifugation (4000g for 90 min).
After discarding the supernatant, the nanoparticles were resuspended in PhosphateBuffered Saline (PBS).
Statistical analysis
Statistical comparisons were made using two-tailed Student’s t-test. When more than
two groups were analyzed, one-way or two-way analysis of variance (ANOVA) was used.
P<0.05 was considered to be significant (*) as indicated in figure legends. All treatment
groups were compared to vehicle/control unless mentioned otherwise. Experimental
values were reported as the means with +/-S.E.M (standard error of mean). All
calculations of statistical signiﬁcance were made using GraphPad software. Sampe sizes
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and statistical analysis chosen were based on our previous experience and
recommendations of biostatistician (4, 50, 56).
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Figure Legends
Fig. 1. Loss of primary cilia promotes astrocyte proliferation in a growth factordependent manner.
(A) Representative image of the cilium formed by primary human astrocyte (HA),
stained for acetylated α-tubulin (AcTub, cilium marker) and γ-tubulin (γTub, basal body
marker); scale bar – 10μm. (B) Quantification of primary astrocytes forming cilium, as in
(A), in regular serum-supplemented media (SSM) or upon 48h of serum starvation (SFM);
300 cells, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05. (C)
Western blot of IFT88 and KIF3B in primary and immortalized astrocytes (HA-LTA) stably
expressing non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B. (D, E)
Quantification of primary astrocytes (D) and immortalized astrocytes (E) forming primary
cilium, as in (B) upon depletion of IFT88 or KIF3B, as in (C); 300 cells, 100 cells in each
of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (F,
G) Growth rates of primary astrocytes (F) and immortalized astrocytes (G) upon depletion
of IFT88 or KIF3B in full media or in serum-free conditions (SFM); 3 independent
experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05.
Fig. 2. Loss of cilium promotes increased ERK1/2 phosphorylation in response
to serum stimulation.
(A) Experiment schematics (top) and representative images of cells stably expressing
non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated αtubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body marker), and ERK1/2
phosphor-T202/Y204 (pERK1/2) ; scale bar – 10μm. (B, C, D) Quantifications of ERK1/2
phosphor-T202/Y204 intensities in whole cells (B), nuclei (C) and cytoplasm (D) as in (A);
100 cells in 3 independent experiments; two-way ANOVA with Dunnett’s post hoc test,
p<0.05. (E) Representative western blot analysis of cells as in (A), stained for ERK1/2
phosphor-T202/Y204, total ERK1/2, and GAPDH. (F) Quantifications of ERK1/2
phosphor-T202/Y204 bands intensities, as in (E).
Fig. 3. Loss of cilium promotes decreased AKT phosphorylation in response to
serum stimulation.
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(A) Experiment schematics (top) and representative images of cells stably expressing
non-targeting shRNA (Con) or shRNA against IFT88 or KIF3B, stained for acetylated αtubulin (AcTub), γ-tubulin (γTub), and AKT phosphor-S473 (pAKT) ; scale bar – 10μm.
(B, C, D) Quantifications of AKT phosphor-S473 intensities in whole cells (B), nuclei (C)
and cytoplasm (D) as in (A); 100 cells in 3 independent experiments; two-way ANOVA
with Dunnett’s post hoc test, p<0.05. (E) Representative western blot analysis of cells as
in (A), stained for AKT phosphor-S473, total AKT, and GAPDH. (F) Quantifications of AKT
phosphor-S473 bands intensities, as in (E).
Fig. 4. Lysophosphatidic acid promotes proliferation in deciliated astrocytes.
(A) Growth rates of immortalized astrocytes stably expressing non-targeting shRNA
(Con) or shRNA against IFT88 or KIF3B in serum-supplemented media (SSM), media
supplemented with charcoal-stripped serum (cSSM), or in serum-free conditions (SFM);
3 independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (B)
Growth rates of cells as in (A) in serum-supplemented media (SSM), serumsupplemented media supplemented with 10μmol/L Ki16425, serum-free media
supplemented with 1μmol/L LPA (SFM LPA), or in serum-free conditions (SFM); 3
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (C)
Experiment schematics (top) and representative western blot analysis of cells as in (A)
stained for ERK1/2 phosphor-T202/Y204, total ERK1/2, AKT phosphor-S473, total AKT,
and α-tubulin. (D) Quantifications of ERK1/2 phosphor-T202/Y204 bands intensities, as
in (C). (E) Quantifications of AKT phosphor-S473 bands intensities, as in (C). (F) Growth
rates of cells as in (A) SSM, SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, and
B27 supplement (SFM-GF), SFM supplemented with 20ng/ml EGF, 20ng/ml bFGF, B27
supplement and 1μmol/L LPA (SFM-GF LPA), or in serum-free conditions (SFM); 3
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05.
Fig. 5. Intracellular localization of LPA signaling cascade components.
(A) Representative images of immortalized astrocytes expressing exogenous
3xFLAG-LPAR1/LPAR3/LPAR6, stained for acetylated α-tubulin (AcTub, cilium marker),
γ-tubulin (γTub, basal body marker) and FLAG-tag, arrowheads indicate primary cilium;
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scale bar – 10μm (B) Representative images of immortalized astrocytes stained for
acetylated α-tubulin (AcTub), γ-tubulin (γTub), Gαs, Gαq, Gα12 and Gαi1, arrowheads
indicate primary cilium; scale bar – 10μm. (C) Immunoprecipitation of 3xFLAG tagged
LPAR1 expressed in immortalized astrocytes stably expressing non-targeting shRNA
(Con) or shRNA against IFT88 or KIF3B in serum-free conditions. (D) Schematic of
potential mechanism of primary cilium restrictive action on the proliferative component of
LPA signaling.
Fig. 6. Inhibition of LPA signaling suppresses proliferation of GBM PDXs in vivo.
(A) Representative images of mice subcutaneously injected with GBM6 (left panel)
and GBM12 (right panel) and administered with vehicle or 30mg/kg/day Ki16425. (B, C)
Analysis of tumor growth as in (A) for GBM6 (B) and GBM12 (C); 5 mice per group; twoway ANOVA with Sidak’s post hoc test, p<0.05. (D, E) Analysis of GBM6 (D) and GBM12
(E) terminal tumor weight; 5 tumors per group; Student’s t-test, p<0.05. (F, G)
Representative images of GBM6 (F) and GBM12 (G), stained with DAPI; arrowheads
indicate mitotic cells; scale bar – 20μm. (H, I) Quantification of mitotic figures as in (F, G)
for GBM6 (H) and GBM12 (I); at least 1000 cells within 10 random fields per group;
Student’s t-test, p<0.05.
Fig. 7. Targeted brain delivery of Ki16425 suppresses GBM PDX growth in an
intracranial model.
(A) Representative MRI images of mice bearing intracranially grafted GBM12
throughout the treatment with PEG-PLGA nanoparticles loaded with Ki16425 (30mg/kg
twice a day); scale bar – 5mm. (B) Analysis of tumor growth as in (A); 5 mice per group;
two-way ANOVA with Sidak’s post hoc test, p<0.05. (C) Quantification of mitotic figures
as in (D); at least 1000 cells within 10 random fields per group; Student’s t-test, p<0.05.
(D) Representative images of tumors from (A), stained with DAPI; arrowheads indicate
mitotic cells; scale bar – 20μm.
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Supplementary Materials and Methods.
Generation of CRISPR-Cas9 driven LPAR1 knock out in astrocytes.
sgRNA targeting LPAR1 were designed using Broad institute web tool:
https://portals.broadinstitute.org/gpp/public/analysis-tools/sgrna-design; synthesized as
separate oligo nucleotides and cloned into pLentiCRISPR v2 (1) (a gift from Feng Zhang
(Addgene plasmid # 52961)). Lentiviral particles were produced as previously described
(2). Immortalized astrocytes were infected and selected on 1 µg/ml of puromycin until
stable clones were formed. Individual cloned were established and tested for LPAR1
expression.
1.

Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for

CRISPR screening. Nature methods. 2014;11(8):783-4.
2.

Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1-

dependent Aurora A activation induces disassembly of the primary cilium. Cell.
2007;129(7):1351-63.
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target
acetyated

cat.#

host
species

company

application

dilution

T6793

mouse

Sigma

IF, F-IHC

1:1000

5335S

rabbit

Cell Signaling

IF

1:500

gamma tubulin

sc-7396

goat

Santa Cruz

IF, F-IHC

1:500

IFT88

60227-1-Ig

mouse

Proteintech

WB

1:1000

Kif3B

sc-50456

rabbit

Santa Cruz

WB

1:500

alpha tubulin

16199

mouse

Sigma

WB

1:40000

9101

rabbit

Cell Signaling

IF, WB

1:200, 1:1000

ERK1/2

4695

rabbit

Cell Signaling

WB

1:1000

GAPDH

MAB374

mouse

Millipore

WB

1:80000

pAKT S473

AF887

rabbit

R&D Systems

IF, WB

1:100, 1:500

AKT

2920

mouse

Cell Signaling

WB

1:1000

FLAG

F1804

mouse

Sigma

IF, WB

1:500, 1:1000

FLAG

PA1-984B

rabbit

IF, WB

1:500, 1:1000

G alpha s

sc-135914

mouse

Santa Cruz

IF, WB

1:100, 1:500

G alpha q

sc-393

rabbit

Santa Cruz

IF, WB

1:200, 1:1000

G alpha 12

sc-409

rabbit

Santa Cruz

IF, WB

1:100, 1:200

G alpha i1

sc-391

rabbit

Santa Cruz

IF, WB

1:100, 1:500

Arl13b

17711-1-AP

rabbit

Proteintech

IF, F-IHC

1:400, 1:200

LPAR1

20442-1-AP

rabbit

Proteintech

IF

1:100

LPAR1

10005280

rabbit

Cyman chemicals

WB

1:250

LPAR1

sc-515665

mouse

Santa Cruz

IF

1:100

alpha tubulin
acetyated
alpha tubulin

pERK1/2
T202/204

Thermo Fisher
Scientific
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name

clone ID

targeting sequence

vector

company

shIFT88#1

V3LHS_338157 GGAATAACACTGACCACCT

pGIPZ

Dharmacon

shIFT88#2

V3LHS_338155

AGCATCTGAATACTGACCA

pGIPZ

Dharmacon

shKif3B#1

V3LHS_644788

TTGCTAGTCTCTTCTCTCA

pGIPZ

Dharmacon

shKif3B#2

V3LHS_635533

ATCTCATCTTCATCCTGCA

pGIPZ

Dharmacon

Supplementary table 2

68

name
BamHILPAR1
LPAR1TGA-XhoI
BamHILPAR3
LPAR3TGA-XhoI
BamHILPAR6
LPAR6TGA-XhoI

sequence

company

ATTGGATCCATGGCTGCCATCTCTACTTCC

IDT Technologies

ATTCTCGAGTCAAACCACAGAGTGGTCATTGC

Invitrogen

ATTGGATCCATGAATGAGTGTCACTATGACAAGC

IDT Technologies

ATTCTCGAGTCAGGAAGTGCTTTTATTGCAGACTG

Invitrogen

ATTGGATCCATGGTAAGCGTTAACAGCTCC

IDT Technologies

ATTCTCGAGTCAGGCAGCAGATTCATTGTCAAATATC

Invitrogen

GATCCTAAGCTTACCGGTATGAAGACGATCATCGCCCTGAGCT
ER-3xFlag-

ACATCTTCTGCCTGGTATTCGCCATGGACTACAAAGACCATGA

MCS

CGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGAT

(forward

GACAAGGGAGGTGGAGGCGGTGGAGGATCCTGTACAGCTAG

strand)

CGAATTCTGCAGATATCGGCGCGCCGTTTAAACACGCGTCTC

Invitrogen

GAGTGATTAATTAAGGTCGACGATCCT
sgLPAR1_F
sgLPAR1_
R

caccgTCTTTGGCTATGTTCGCCAG

Invitrogen

aaacCTGGCGAACATAGCCAAAGAc

Invitrogen
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Study 2: The role of KIF2C/AURKA signaling in cilia loss and progression of
glioblastoma.

Yuriy V. Loskutov, Joshua Arnold, Sila Yanardag, Werner J. Geldenhuys and Elena N.
Pugacheva
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Abstract
The primary cilium is a ubiquitous organelle presented on most human cells. It serves
as a crucial signaling hub for multiple pathways including growth factor and G-protein
coupled receptors. Loss of primary cilia was observed in various cancers, however, the
implications of this event are unclear. Our long-term goal is to delineate the molecular
mechanism of primary cilia disassembly under normal and pathological conditions and
determine if the loss of the cilium is required for cancer progression. Aurora kinase A, a
common proto-oncogene often overexpressed in GBM, initiates rapid cilia disassembly,
but the downstream effectors of this pathway still have not been found. One of the
potential AURKA effectors is the motor protein KIF2C, known to directly destabilize
microtubules. AURKA can phosphorylate KIF2C on multiple sites during mitosis,
however, nothing is known about AURKA and KIF2C interaction in non-mitotic cells. We
found that KIF2C overexpression is triggering cilia disassembly in AURKA dependent
manner, and are focusing on elucidating the molecular mechanism of the KIF2C driven
cilia disassembly. Phosphorylation of KIF2C on S715 by AURKA was reported to
enchance spindle pole microtubule targeting. Both spindle pole and axonemal
microtubules are highly post-translationally modified, thus our central hypothesisis that
AURKA-dependent phosphorylation of KIF2C on S715 leads to increased affinity towards
post-translationally modified microtubules (acetylated and/or detyrosinated), and cilia
disassembly, resulting in increase in cell proliferation and tumor progression.
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Introduction
Glioblastoma multiforme (GBM) is one of the most deadly cancers for which no
effective treatment strategy currently exists. The primary cilium is a ubiquitous
microtubule-based organelle that protrudes from the apical surface of most human cells
serving as a cellular antenna for signal transduction and is an important regulator of
mitosis. Cilia are lost in many types of cancer including GBM (1-6). The importance of
cilia loss for cancer progression is largely unknown, although several attempts to rescue
ciliation in cancer cells reveal the therapeutic benefit behind primary cilia restoration (7,
8). The long-term goal of this study is to delineate the molecular mechanism of primary
cilia disassembly under normal and pathological conditions and determine if the loss of
cilium is required for cancer progression. This knowledge is critical for the development
of new therapeutic strategies to prevent and eradicate tumor growth. Aurora kinase A
(AURKA or AurA), a common proto-oncogene that is often overexpressed in GBM (9-12),
initiates rapid cilia disassembly (7, 13), but the downstream effectors of this pathway have
still not been found. One potential AURKA effector is the motor protein KIF2C, known to
directly destabilize microtubules. KIF2C and its family member KIF2A were shown to
promote cilium disassembly upon overexpression (14). KIF2C is phosphorylated by
AURKA, which promotes its localization to highly post-translationally-modified spindle
pole microtubules (15). Axonemal microtubules bear similar post-translational
modifications as spindle pole microtubules and are usually detyrosinated (16).
Interestingly, KIF2C has decreased activity towards detyrosinated microtubules (17),
thus, the central hypothesis of this study is that AURKA-dependent phosphorylation of
KIF2C leads to a change in substrate preference and cilia disassembly, resulting in an
increase in cell proliferation and tumor progression. Rescue of ciliation will inhibit
proliferation, disease progression, and also potentially, recurrence. This hypothesis was
tested through the execution of the following aims:
Aim #1: Determine the mechanism/s of KIF2C-driven deciliation. The working
hypothesis is that AURKA phosphorylation promotes KIF2C translocation from the
cytoplasm to the primary cilium, where it orchestrates the disassembly of axonemal
microtubules.
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Aim #2: Determine the therapeutic benefits of combination therapy of KIF2C depletion
and AURKA inhibition in the treatment of glioblastoma in patient-derived xenograft (PDX)
models. The hypothesis is that the combination of KIF2C depletion and inhibition of
AURKA will synergistically increase the incidence of primary cilia in cancer cells, as well
as decrease tumor growth and potentially, recurrence. The rationale for the proposed
work is that it will elucidate new mechanisms driving cilia disassembly, provide insight
into the critical role of the primary cilia in cancer progression, and reveal new strategies
for a targeted treatment of cancer.
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Materials and methods
Cell lines and reagents
Human astrocytes isolated from human cortex (1800) were obtained from ScienCell
Research Labs and maintained in DMEM/F12 supplemented with 10% heat-inactivated
FBS, Antibiotic-Antimycotic (ThermoFisher), and 10 μg/ml of gentamycin (MP
Biomedicals). Cells were propagated and cryopreserved at passage 2; for all studies,
cells were not passaged more than 10 times or 8 weeks, and no authentication or
mycoplasma testing were performed. For immortalization, primary astrocytes at passage
5 or 6 were cultured until 50–75% confluency and transfected with SV40 large T-antigen
construct (18) followed by selection with 500μg/ml G418 (Sigma) until resistant colonies
were formed. RPE1 hTert cells were obtained from ATCC and cultured according to
ATCC recommendations. U87MG and U373MG were a kind gift from Dr. Daniel C. Flynn
and were also maintained according to ATCC recommendations. GBM6 and 12 PDXs
(19) were kindly provided by Dr. Jann Sarkaria (Mayo Clinic, Rochester, MN) through a
shared MTA agreement, and no authentication or mycoplasma testing were performed.
PDXs were used for cell culture isolation as previously described (20). A list of antibodies
and their used applications is outlined in Table 1. shRNA constructs were obtained from
Dharmacon and are outlined in Table 2. All primers were purchased from IDT
Technologies, the sequences of which are reported in Table 3. MLN8237 (Selleckchem)
and Tubastatin A (Selleckchem) were also used.
Western blotting
Western blotting was performed using standard procedures (21). Primary antibodies
that were used are outlined in Table 1. Secondary anti-mouse and anti-rabbit HRPconjugated antibodies (Jackson ImmunoResearch Labs) were diluted 1:10,000 followed
by chemiluminescence-based detection with HyGLO™ (Denville Scientific). Bands were
quantified using the digital electrophoresis documentation and image analysis software
GeneTools (Syngene Corp.) with signal intensity normalized to α-tubulin.
Immunofluorescent cell analysis
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Cells were processed as previously described (13). Primary antibodies that were used
are outlined in Table 1. Secondary antibodies included AlexaFluor 488, 555, and 647
(ThermoFisher). Images were captured using a standard setting by an LSM510 confocal
microscope (Zeiss) (21). All images represent whole-cell 3D reconstructed projections
with 0.4μm steps. All quantifications were done using ImageJ (NIH).
KIF2C cloning and cell lines generation
KIF2C cDNA was purchased from PlasmID, PCR-amplified, and cloned into pEGFP
(Clontech) vector between EcoRI and XhoI restriction sites. For inducible expression,
EGFP-KIF2C fusion cDNA was cloned into pLUTZ lentivirus vector between AgeI and
XhoI restriction sites (22). All constructs were validated by sequencing.
Lentiviral particles were produced as previously described (13). Cells were infected
and selected with correspondent antibiotics until stable clones were formed.
Cell growth/proliferation analysis
Cell growth rate was determined using semi-automated cell counting in ImageJ (NIH).
Cells were plated at 1x104 cells per well and grown in the specified conditions for five
days, fixed with methanol, and stained with Hoechst33342. Four random 10x fields per
well were analyzed with at least three replicates per independent experiment; each graph
represents at least three independent experiments.
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Results
KIF2C overexpression drives cilia disassembly in an AURKA-dependent
manner.
To test whether overexpression of KIF2C can cause loss of primary cilium, we
generated RPE1-hTert and human immortalized astrocytes with inducible overexpression
of GFP-tagged KIF2C. In both cell lines, overnight induction of KIF2C expression under
ciliated, serum pre-starved conditions resulted in robust disassembly of primary cilia
(Fig.1A, B). To test if cilium disassembly was KIF2C dose-dependent, time course
experiments with limited KIF2C induction times were performed. The time course
experiment revealed robust KIF2C dose-dependent disassembly of primary cilia (Fig.1CD).
To test if AURKA plays a role in KIF2C-driven cilia disassembly, a small molecule
inhibitor highly specific for AURKA called MLN8237 was used. Inhibition of AURKA and
simultaneous induction of KIF2C significantly attenuated KIF2C-driven cilia disassembly
(Fig.1E), suggesting that AURKA activity is required. Interestingly, KIF2C was noted to
be present inside the primary cilium in several cells, and its presence was associated with
decreased acetylated tubulin staining in the same area (Fig.1F). These data argue that
KIF2C enters primary cilium prior to disassembling it.
Ciliated cells are likely to be more a differentiated cell population within GBM.
GBM tumor cells have decreased ciliation, but nevertheless up to 10% of GBM tumor
cells possess primary cilia in vivo (23). This was confirmed for two PDX-derived GBM
primary cell lines GBM6 and GBM12 (Study 1); these cell lines represent classical and
mesenchymal subtypes of GBM, respectively, and were chosen due to their high
expression of AURKA and KIF2C and the worst prognosis. To test if the ciliated population
of GBM cells had any associated phenotype, Sox2 and CD44 expression was analyzed.
Sox2 is enriched in self-renewing neural progenitor cells (24), and its loss in GBM tumorinitiating cells causes abrogation of proliferation and tumorigenicity (25). CD44 is highly
enriched in neural stem cells (26).The ciliated population of both GBM6 and 12 had only
about 5% CD44-positive and 60% Sox2-positive cells, versus 40% and 80% in non-
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ciliated cells, respectively (Fig.2A-C), suggesting that this population is more
differentiated and less proliferative.
Depletion of KIF2C or inhibition of AURKA inhibit GBM cell proliferation and
restore ciliation.
To test if KIF2C has any effect on the proliferation of GBM cells, we generated U87MG
cells with stable shRNA-driven depletion of KIF2C (Fig.3A). All cell sublines had at least
an 80% depletion of KIF2C, and proliferated significantly slower compared to the control
cell line (Fig.3B).Since AURKA activity is required for KIF2C-driven cilia disassembly, it
was tested whether the inhibition of AURKA can restore ciliation. Inhibition of AURKA for
24h with 50nM of MLN8237 was sufficient to cause a twofold increase in the ciliation of
U87MG cells (Fig.3C) and also inhibit proliferation (Fig.3D). In PDX-derived GBM primary
cells, incubation with MLN8237 for 24h was sufficient to increase ciliation of GBM6 cells
up to 60%, as compared to 10-20% in the DMSO control group (Fig.3E). Interestingly,
there were no changes in the total number of mitotic figures, however, half of the mitotic
figures in MLN8237-treated cells represented characteristic abnormalities such as
monopolar spindles (Fig.3F-G).
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Future directions
Validation of GFP-KIF2C data with untagged KIF2C.
Data obtained from this study indicates that overexpression of GFP-KIF2C is sufficient
to induce cilia disassembly (Fig.2), however, the level of overexpressed protein is much
higher than the endogenous KIF2C level (Fig.2C). This can be explained by decreased
depolymerization activity of EGFP-KIF2C (27) or the potential suppression of EGFPKIF2C cilia entry due to size exclusion (28). To address this issue, KIF2C cDNA was
cloned into pLUTZ vector between EcoRI and XhoI restriction sites, allowing for the
inducible expression of KIF2C without a tag. Utilization of this construct will allow the
confirmation of previously obtained results, and clarify if KIF2C triggers cilia disassembly
in a more physiological range. It is expected that lower levels of KIF2C trigger cilia
disassembly, as well as more abundant KIF2C entry into the cilium.
Evaluating the effects of S715 phosphorylation on KIF2C activity in vivo.
To test whether phosphorylation status of KIF2C at the S715 site has an effect on cilia
disassembly, we generated a series of KIF2C mutants: KIF2C-S715A (phosphor-dead),
KIF2C-S715E (phosphor-mimicking) and KIF2C-KVD (microtubule disassembly-impaired
(29)) in pLUTZ vector (Fig.4A). Utilization of these constructs will allow for evaluation if
S715 phosphorylation effects the ability of KIF2C to disassemble primary cilia. It is
expected that KIF2C-S715E will be more effective in cilium disassembly than KIF2C-wt,
while KIF2C-S715A will be less effective in cilium disassembly than KIF2C-wt. KIF2CKVD will be utilized as negative control, since its overexpression is not expected to
produce any effect on primary cilia. In addition, since KIF2C-KVD is supposed to be
targeted to the cilium as well as KIF2C-wt, it is expected to see accumulation of KIF2CKVD at the tip/along the primary cilium upon overexpression.
Evaluating the effects of S715 phosphorylation on KIF2C depolymerization
activity in vitro.
To test whether the phosphorylation status of KIF2C at the S715 site has an effect on
in vitro microtubule depolymerization activity, cDNA for KIF2C wt, KIF2C S715A, S715E
and KVD) was cloned in pcDNA3.1 6His-Flag vector (Fig.4B). This system allows to
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express KIF2C and the mutants in HEK293T cells (Fig.4C). Future plans call for purifying
the indicated proteins and using them for in vitro microtubule depolymerization assays
(30). It is not expected to see any difference in depolymerization activity between KIF2Cwt, KIF2C-S715A, and KIF2C-S715E, since tubulin available on the market consists of a
mixture of tyrosinated and detyrosinated isoforms. To evaluate the substrate preference
of KIF2C and its mutants, tyrosinated and detyrosinated tubulin dimers will be purified
using previously described methodology (31). In experiments with tyrosinated tubulin, it
is expected to see strong disassembly with KIF2C-wt, KIF2C-S715A, and KIF2C-S715E,
while detyrosinated tubulin is predicted to be more resistant to KIF2C-wt and KIF2CS715A (17), but more sensitive to KIF2C-S715E (15).
Evaluating the effects of KIF2C and AURKA depletion on the ciliation status of
GBM PDXs in vivo and in vitro.
To test whether depletion of KIF2C can restore ciliation in GBM PDXs, previously
validated shRNA against KIF2C (Fig.3) will be subclonedfrom pGIPZ vectors into pTRIPZ
vectors according to the manufacturer protocol to allow for inducible KIF2C depletion.
Inducible shRNA against KIF2C will be introduced in GBM6 and GBM12 primary cultures
and selected with puromycin. Selected cells will be injected into NSG mice for PDX
amplification as described previously (20). Amplified PDXs will be validated for KIF2C
depletion and used for in vivo and in vitro assessment of ciliation and proliferation. It is
expected that primary cilia in GBM PDXs will be restored and severely suppress
proliferation both in vitro and in vivo. Since the study data indicates that KIF2C-driven cilia
disassembly is AURKA dependent (Fig.1E), inhibition of AURKA in conjunction with
KIF2C depletion will be tested for their combined ability to restore ciliation and inhibit
cancer cell proliferation. It is expected that better primary cilia restoration will occur with
combination of AURKA inhibition and KIF2C depletion than with KIF2C depletion alone,
since AURKA activation can initiate HDAC6-dependent cilia disassembly (13).
Development of small molecule inhibitor for KIF2C.
To develop an anti-KIF2C specific inhibitor, virtual screen of compounds was
performed utilizing the publicly available crystal structure of the KIF2C motor domain
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(https://www.ncbi.nlm.nih.gov/Structure/pdb/2HEH). The 11 compounds (Table 4) with
the highest fitting scores from this screen will be utilized in in vitro microtubule
depolymerization assays. The compounds with the best ability to inhibit KIF2C-driven
depolymerization will be tested further for their ability to inhibit KIF2C-driven cilia
disassembly in cells, along with their effect on cell viability. Compounds showing the best
results in these assays will be tested in their ability to restore primary cilium and suppress
proliferation of PDX GBMs in vitro and in vivo.
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Discussion
Loss of the primary cilium seems to have a significant role in maintaining a highly
proliferative phenotype in cancer (7, 8). At the same time, inhibition of primary cilia
formation does not play a significant role in GBM tumor cell proliferation both in vitro and
in vivo (27), and moreover, these findings argue that these cells are more differentiated
(Fig.2). Targeting cancer cells in order to restore primary cilia is therefore expected to
dampen proliferation and force re-differentiation of the cancer cells. Currently, the exact
machinery participating in the disassembly of primary cilia has remained unknown, but
this study establishes that KIF2C can enter primary cilium and promote disassembly in
an AURKA-dependent manner. Targeting of either KIF2C or AURKA significantly affects
proliferation of cancer cells. Elucidation of AURKA and KIF2C interactions that help
promote primary cilia disassembly will allow for the development of new targeted
therapies by preventing cilia loss of cancer cells.

81

References
1.
Basten SG, Willekers S, Vermaat JS, Slaats GG, Voest EE, van Diest PJ, et al.
Reduced cilia frequencies in human renal cell carcinomas versus neighboring
parenchymal tissue. Cilia. 2013;2(1):2.
2.
Egeberg DL, Lethan M, Manguso R, Schneider L, Awan A, Jorgensen TS, et al.
Primary cilia and aberrant cell signaling in epithelial ovarian cancer. Cilia. 2012;1(1):15.
3.
Hassounah NB, Nagle R, Saboda K, Roe DJ, Dalkin BL, McDermott KM. Primary
cilia are lost in preinvasive and invasive prostate cancer. PloS one. 2013;8(7):e68521.
4.
Moser JJ, Fritzler MJ, Rattner JB. Primary ciliogenesis defects are associated with
human astrocytoma/glioblastoma cells. BMC cancer. 2009;9:448.
5.
Radford R, Slattery C, Jennings P, Blacque O, Pfaller W, Gmuender H, et al.
Carcinogens induce loss of the primary cilium in human renal proximal tubular epithelial
cells independently of effects on the cell cycle. American journal of physiology Renal
physiology. 2012;302(8):F905-16.
6.
Seeley ES, Carriere C, Goetze T, Longnecker DS, Korc M. Pancreatic cancer and
precursor pancreatic intraepithelial neoplasia lesions are devoid of primary cilia. Cancer
research. 2009;69(2):422-30.
7.
Gradilone SA, Radtke BN, Bogert PS, Huang BQ, Gajdos GB, LaRusso NF.
HDAC6 inhibition restores ciliary expression and decreases tumor growth. Cancer
research. 2013;73(7):2259-70.
8.
Yang Y, Roine N, Makela TP. CCRK depletion inhibits glioblastoma cell
proliferation in a cilium-dependent manner. EMBO reports. 2013;14(8):741-7.
9.
Barton VN, Foreman NK, Donson AM, Birks DK, Handler MH, Vibhakar R. Aurora
kinase A as a rational target for therapy in glioblastoma. Journal of neurosurgery
Pediatrics. 2010;6(1):98-105.
10.
Hong X, O'Donnell JP, Salazar CR, Van Brocklyn JR, Barnett KD, Pearl DK, et al.
The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation
of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of
temozolomide and ionizing radiation. Cancer chemotherapy and pharmacology.
2014;73(5):983-90.
11.
Lehman NL, O'Donnell JP, Whiteley LJ, Stapp RT, Lehman TD, Roszka KM, et al.
Aurora A is differentially expressed in gliomas, is associated with patient survival in
glioblastoma and is a potential chemotherapeutic target in gliomas. Cell cycle.
2012;11(3):489-502.
12.
Samaras V, Stamatelli A, Samaras E, Arnaoutoglou C, Arnaoutoglou M, Stergiou
I, et al. Comparative immunohistochemical analysis of aurora-A and aurora-B expression
in human glioblastomas. Associations with proliferative activity and clinicopathological
features. Pathology, research and practice. 2009;205(11):765-73.
13.
Pugacheva EN, Jablonski SA, Hartman TR, Henske EP, Golemis EA. HEF1dependent Aurora A activation induces disassembly of the primary cilium. Cell.
2007;129(7):1351-63.
14.
Miyamoto T, Hosoba K, Ochiai H, Royba E, Izumi H, Sakuma T, et al. The
Microtubule-Depolymerizing Activity of a Mitotic Kinesin Protein KIF2A Drives Primary
Cilia Disassembly Coupled with Cell Proliferation. Cell reports. 2015.

82

15.
Zhang X, Ems-McClung SC, Walczak CE. Aurora A phosphorylates MCAK to
control ran-dependent spindle bipolarity. Molecular biology of the cell. 2008;19(7):275265.
16.
Janke C, Bulinski JC. Post-translational regulation of the microtubule cytoskeleton:
mechanisms and functions. Nature reviews Molecular cell biology. 2011;12(12):773-86.
17.
Peris L, Wagenbach M, Lafanechere L, Brocard J, Moore AT, Kozielski F, et al.
Motor-dependent microtubule disassembly driven by tubulin tyrosination. The Journal of
cell biology. 2009;185(7):1159-66.
18.
Schuermann M. An expression vector system for stable expression of oncogenes.
Nucleic acids research. 1990;18(16):4945-6.
19.
Carlson BL, Grogan PT, Mladek AC, Schroeder MA, Kitange GJ, Decker PA, et al.
Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
International journal of radiation oncology, biology, physics. 2009;75(1):212-9.
20.
Carlson BL, Pokorny JL, Schroeder MA, Sarkaria JN. Establishment, maintenance
and in vitro and in vivo applications of primary human glioblastoma multiforme (GBM)
xenograft models for translational biology studies and drug discovery. Current protocols
in pharmacology. 2011;Chapter 14:Unit 14 6.
21.
Kozyreva VK, Kiseleva AA, Ice RJ, Jones BC, Loskutov YV, Matalkah F, et al.
Combination of Eribulin and Aurora A Inhibitor MLN8237 Prevents Metastatic
Colonization and Induces Cytotoxic Autophagy in Breast Cancer. Molecular cancer
therapeutics. 2016;15(8):1809-22.
22.
Ice RJ, McLaughlin SL, Livengood RH, Culp MV, Eddy ER, Ivanov AV, et al.
NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A
inhibitors: implications for treatment of metastatic solid tumors. Cancer research.
2013;73(10):3168-80.
23.
Sarkisian MR, Siebzehnrubl D, Hoang-Minh L, Deleyrolle L, Silver DJ,
Siebzehnrubl FA, et al. Detection of primary cilia in human glioblastoma. Journal of neurooncology. 2014;117(1):15-24.
24.
Hagey DW, Muhr J. Sox2 acts in a dose-dependent fashion to regulate proliferation
of cortical progenitors. Cell reports. 2014;9(5):1908-20.
25.
Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al.
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss
of tumorigenicity. Stem cells. 2009;27(1):40-8.
26.
Pollard SM, Wallbank R, Tomlinson S, Grotewold L, Smith A. Fibroblast growth
factor induces a neural stem cell phenotype in foetal forebrain progenitors and during
embryonic stem cell differentiation. Molecular and cellular neurosciences.
2008;38(3):393-403.
27.
Helenius J, Brouhard G, Kalaidzidis Y, Diez S, Howard J. The depolymerizing
kinesin MCAK uses lattice diffusion to rapidly target microtubule ends. Nature.
2006;441(7089):115-9.
28.
Lin YC, Niewiadomski P, Lin B, Nakamura H, Phua SC, Jiao J, et al. Chemically
inducible diffusion trap at cilia reveals molecular sieve-like barrier. Nature chemical
biology. 2013;9(7):437-43.

83

29.
Ogawa T, Nitta R, Okada Y, Hirokawa N. A common mechanism for microtubule
destabilizers-M type kinesins stabilize curling of the protofilament using the class-specific
neck and loops. Cell. 2004;116(4):591-602.
30.
Mirigian M, Mukherjee K, Bane SL, Sackett DL. Measurement of in vitro
microtubule polymerization by turbidity and fluorescence. Methods in cell biology.
2013;115:215-29.
31.
Lafanechere L, Job D. Preparation of pure tyrosinated or detyrosinated tubulin
isoforms. Methods in molecular biology. 2011;777:71-86.
32.
Hoang-Minh LB, Deleyrolle LP, Siebzehnrubl D, Ugartemendia G, Futch H, Griffith
B, et al. Disruption of KIF3A in patient-derived glioblastoma cells: effects on ciliogenesis,
hedgehog sensitivity, and tumorigenesis. Oncotarget. 2016;7(6):7029-43.

84

Fig. 1. KIF2C overexpression drives cilia disassembly in an AURKA-dependent
manner.
(A) Representative image of RPE1-hTert cells with (left-bottom corner) and without
overexpression of GFP-KIF2C, stained for acetylated α-tubulin (AcTub, cilium marker)
and KIF2C; scale bar – 10μm. Arrow indicates primary cilium. (B) Quantification of cilium
in cells with (Dox+) without (Dox-) induction of EGFP-KIF2C expression as in (A) upon
24h of serum starvation; 300 cells total, 100 cells in each of 3 independent experiments;
Student’s t-test, p<0.05. (C) Western blot of KIF2C in RPE1-hTert cells after 24h of serum
starvation and induction of EGFP-KIF2C expression for the indicated number of hours.
(D) Quantification of cells forming primary cilium upon induction of GFP-KIF2C expression
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for the indicated number of hours as in (C); 300 cells total, 100 cells in each of 3
independent experiments; one-way ANOVA with Dunnett’s post hoc test, p<0.05. (E)
Quantification of cells forming primary cilium as in (B) upon induction of GFP-KIF2C
expression for 16h in the presence or absence of 50nM MLN8237; 300 cells total, 100
cells in each of 3 independent experiments; one-way ANOVA with Dunnett’s post hoc
test, p<0.05. (F) Representative image of the primary cilium in human astrocytes after
48h of serum starvation, followed by 8h induction of GFP-KIF2C expression, stained for
acetylated α-tubulin (AcTub, cilium marker) and KIF2C; scale bar – 10μm. Arrow indicates
KIF2C accumulation in primary cilium.
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Fig. 2. Stem-cell/differentiation marker status of ciliated cells is different from
cells without primary cilia.
(A) Representative image of GBM6 and GBM12 cells with and without primary cilia
stained for acetylated α-tubulin (AcTub, cilium marker), γ-tubulin (γTub, basal body
marker), and CD44 (neural stem-cell marker); scale bar – 10μm. (B) Quantification of
CD44+ cells as in (A); 200 cells total, 100 cells in each of 2 independent experiments;
Student’s t-test, p<0.05. (C) Quantification of Sox2+ cells; 200 cells total, 100 cells in each
of 2 independent experiments; Student’s t-test, p<0.05.
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Fig. 3. Effects of KIF2C depletion and inhibition of AURKA on GBM cell
proliferation and ciliation.
(A) Western blot of KIF2C in U87MG cells stably-expressing shRNA against KIF2C.
(B) Growth curve of U87MG cells as in (A); slopes of the fitted lines significantly different
in F-test, * p<0.05 (C) Quantification of cilium in U87MG cells treated with 50nM MLN8237
or 15μM Tubastatin A; 500 cells total, 250 cells in each of 2 independent experiments;
one-way ANOVA with Dunnett’s post hoc test, p<0.05. (D) Growth curve of U87MG cells
as in (C); slopes of the fitted lines significantly different in F-test, * p<0.05. (E)
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Quantification of GBM6 cells forming primary cilium in the presence of 50nM MLN8237;
300 cells total, 100 cells in each of 3 independent experiments; Student’s t-test, p<0.05.
(F) Representative image of the mitotic figures in GBM6 cells as in (E). Top image depicts
normal mitotic figure, and bottom image depicts abnormal, monopolar mitotic figure;
stained for acetylated α-tubulin (AcTub, cilium marker) and DAPI; scale bar – 10μm. (G)
Quantification of mitotic figures as in (E and F); 200 cells total, 100 cells in each of 2
independent experiments.
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Fig. 4. KIF2C cloning and protein production.
(A) Map of pLUTZ KIF2C construct.(B) Map of pcDNA3.1 6xHis-Flag KIF2C construct.
(C) Western blot of 6xHis-Flag-KIF2C expressed in HEK293T cells. Cells were lysed in
phosphate-buffered saline with 15mM imidazole.
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Table 1.
target

host

cat.#

species

company

application

dilution

acetyated
alpha

T6793

mouse

Sigma

IF

1:1000

sc-7396

goat

Santa Cruz

IF

1:500

16199

mouse

Sigma

WB

1:40000

sc-9960

mouse

Santa Cruz

IF

1:400

IF

1:400

tubulin
gamma
tubulin
alpha
tubulin
CD44

Cell
Sox2

3579S

rabbit

Signaling
Technology

KIF2C

sc-81305

mouse

Santa Cruz

IF, WB

1:200,
1:1000

Table 2.
name

clone ID

shKIF2C#1 V3LHS_357508

targeting sequence

vector

company

AAACTACTGTCATACTCCT pGIPZ

Dharmacon

shKIF2C#2 V3LHS_357509 TGGAGTTGACGGATCTCCG pGIPZ

Dharmacon

shKIF2C#3

Dharmacon

V2LHS_78032

TTATTTGCAGTCGTCACTG

pGIPZ

Table 3.
name

sequence

company

EcoRI-Kif2C

ATTGAATTCATGGCCATGGACTCG

IDT Technologies

Kif2C-XhoI

ATTCTCGAGTCGTCACTGGGGC

IDT Technologies
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Table 4.
compound ID
7693705
7657128
11300854
63713617
73545990
61771203
97609998
82375256
80994660

compound name
2-{2-[(5-hydroxy-6-methyl-1,2,4-triazin-3yl)thio]ethyl}-1H-isoindole-1,3(2H)-dione
4-(3-{[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl}4-methylphenyl)-2-methyl-1(2H)-phthalazinone
6-({4-[(4-butyl-1H-1,2,3-triazol-1yl)methyl]piperidin-1-yl}carbonyl)-1H-indole
N-(2,1,3-benzothiadiazol-5-ylmethyl)-N-methyl1H-pyrazole-3-carboxamide
3-{2-[4-(2-fluorobenzyl)piperidin-1-yl]-2oxoethyl}dihydropyrimidine-2,4(1H,3H)-dione
3-(2-fluorophenyl)-N-(imidazo[1,2-a]pyrimidin-2ylmethyl)-1H-pyrazole-5-carboxamide
2-amino-4-[5-(1H-pyrazol-3-yl)-2-thienyl]-6-(1Hpyrrol-3-yl)nicotinonitrile
N-[2-(5-amino-1,3,4-thiadiazol-2-yl)ethyl]-5-(2fluorophenyl)pyrazolo[1,5-a]pyrimidin-7-amine
5-[(2-dibenzo[b,d]furan-4-yl-1H-imidazol-1yl)methyl]-1,2,4-oxadiazole-3-carboxamide

company
ChemBridge
ChemBridge
ChemBridge
ChemBridge
ChemBridge
ChemBridge
ChemBridge
ChemBridge
ChemBridge

22763338

4-(2,6-dimethyl-3-pyridinyl)-N-methyl-N-{[3-(3pyridinyl)-5-isoxazolyl]methyl}-2-pyrimidinamine

ChemBridge

81086871

(1-methyl-1H-imidazol-2-yl){3-[6-(1H-pyrazol-1yl)pyrimidin-4-yl]phenyl}methanone

ChemBridge

92

General Discussion
The primary cilium is a crucial organelle for the transduction of multiple signaling
cascades (1-3). Loss of primary cilia is associated with an increase in cell proliferation in
some cell types (3, 4), while suppressing cell proliferation in others (5, 6). In the majority
of cancer types, including GBM, the length and number of primary cilia are significantly
reduced or lost (7-10). Overall, the studies documented in this dissertation present
multiple novel insights into the role of the primary cilium in the regulation of normal and
cancer cell proliferation and in the mechanisms of cilia disassembly. In Study 1, it was
demonstrated that the loss of primary cilia promotes proliferation of human astrocytes in
a growth factor-dependent manner. For the first time, it was demonstrated that spatiotemporal characteristics of the cellular response to growth factors are drastically altered
upon the loss of primary cilia. Previously, PDGF-AA signaling through PDGFRαα was
reported to be lost in deciliated fibroblasts (11), and IGF1R signaling was significantly
reduced (12), thus an increase in proliferation upon the loss of primary cilia is a somewhat
unexpected phenomenon. Other RTKs such as EGFR, FGFR, and Tie1/2 were noticed
to localize to primary cilia (13-17), but the significance of this is unknown. In addition,
different GPCRs can accumulate in the primary cilium (18, 19) along with their
downstream signaling components (20, 21). Therefore, loss of cilia can interfere with
multiple signaling cascades of various modalities, and systematic studies of signaling
alterations are very scarce. In Study 1, LPA was established to be the main non-peptide
growth factor responsible for the increased proliferation of astrocytes with disrupted
ciliogenesis. For the first time, scrutinous analysis of the hyperproliferative phenotype in
cells with an engineered loss of cilia was able to establish the underlining mechanism for
increased proliferation. It was found that LPA-LPAR1 signaling is regulated by primary
cilia. Loss of primary cilia promotes redistribution of LPAR1, which is normally localized
to the cilium, and streamlines signaling through Gα12/Gαq, thus increasing proliferation.
Gα12 and Gαq activation were previously reported to be implicated in cancer cell
proliferation and cancer progression (22, 23). Furthermore, the LPAR1-Gα12 module
specifically was reported to drive ovarian cancer cell proliferation (24). These findings
suggest that primary cilia restricts LPA-LPAR1-driven Gα12/Gαq activation. Loss of cilia in
GBM cells highjacks LPA signaling to maintain a highly proliferative phenotype, rendering
93

them sensitive to inhibition of LPAR1. Utilization of a nanoparticle-based delivery of
Ki16425, a small molecule inhibitor of LPAR1-3, as a monotherapy significantly
decreased GBM growth in vivo. These results clearly indicate that inhibition of LPA
signaling is a viable therapeutic option for GBM control in addition to standard care,
especially in light of the implication of LPA in proliferation and migration/invasion (25, 26).
Currently, the standard of care for GBM patients includes surgical resection of the tumor
and a combination of radiation and chemotherapy (27). Unfortunately, the majority of
patients experience recurrence of the disease within several months (28). Novel
approaches in immunotherapy of GBM seem to be promising, but sustained responses
are still rare (29). In part, this may be due to the prolonged lag period between the initiation
of therapy and the tumor response (30), thus utilization of a tumor growth suppression
agent in combination with an immunotherapeutic approach could be beneficial. Further
studies are required to establish the possibility of combining LPAR inhibitors with
conventional or immuno-based therapies. However, two LPAR inhibitors were recently
used for clinical trials. BMS-986020, an LPAR1 inhibitor, is in Phase 2 clinical trials for
idiopathic pulmonary fibrosis (NCT01766817); and SAR100842, an LPAR1 and 3
inhibitor, is in Phase 2 clinical trials for systemic sclerosis (NCT01651143). If the results
of the current study can be replicated utilizing these compounds, GBM patient survival
could be significantly improved, and disease control would become much easier. Based
on Study 1’s findings, it would be expected to see a substantial increase in recurrencefree survival upon inhibition of LPA signaling in addition to the current standard of care.
Since loss of primary cilia alters a great number of signaling pathways, restoration of
primary cilia in cancer cells could potentially restore proper signaling and induce redifferentiation. So far, several attempts were made to restore cilia in cancer cells, and
results have been very promising (4, 31). However, since the mechanisms of cilia
disassembly are still not fully understood, it is difficult to pursue. Thus, it is crucial to
delineate the pathways involved in cilium loss. Study 2 focused on the role of KIF2C in
the disassembly of cilia. It was found that KIF2C can enter and disassemble primary cilia
in an AURKA-dependent manner. The differentiation/stem marker status of ciliated GBM
cells was evaluated, which confirmed that the cilium is likely to promote re-differentiation
along with halting proliferation. Finally, it was established that targeting of KIF2C and
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AURKA drastically decreases proliferation of GBM cells, and moreover, AURKA inhibition
can robustly restore primary cilia in these cells. AURKA is well known as a master
regulator of cilia disassembly (32), as well as being an important mitotic regulator (33).
Inhibition of AURKA, therefore, can suppress tumor growth in two ways: first, through
direct inhibition of mitosis, and second, through restoration of the primary cilia. KIF2C is
also involved in progression through mitosis, however depletion of KIF2C in nontransformed cells tends to generate a much milder phenotype than in cancer cells (34),
indicating that KIF2C inhibition can potentially yield very little side effects. Further studies
are required to elucidate the exact mechanism of AURKA–KIF2C cooperation in driving
cilia disassembly. Unveiling the mechanisms of cilia disassembly in cancer cells will allow
for the development of novel approaches for anti-cancer therapy. Restoration of primary
cilia in cancer cells is expected to suppress proliferation and initiate re-differentiation, thus
allowing for robust and prolonged disease control.
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